Amedeo Smart

Free Medical Literature Service


 

Amedeo

Chronic Heart Failure

  Free Subscription

Articles published in
Eur J Heart Fail
    September 2021

  1. Corrigendum to 'Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction' [Eur J Heart Fail 2021; 23, 983-991.].
    Eur J Heart Fail. 2021 Sep 12. doi: 10.1002/ejhf.2341.
    >> Share

  2. KAMMERLANDER AA, Nitsche C, Dona C, Koschutnik M, et al
    Heart Failure with Preserved Ejection Fraction after Left-sided Valve Surgery: Prevalent and Relevant.
    Eur J Heart Fail. 2021 Sep 10. doi: 10.1002/ejhf.2345.
    >> Share

  3. MEIJERS WC, Bayes-Genis A, Mebazaa A, Bauersachs J, et al
    Circulating Heart Failure Biomarkers beyond Natriuretic Peptides: updated review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2346.
    >> Share

  4. INCIARDI RM, Solomon SD
    Cardiac Mechanics Assessment and the Risk of Heart Failure in the General Population.
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2342.
    >> Share

  5. HEUSSER K, Wittkoepper J, Bara C, Haverich A, et al
    Sympathetic vasoconstrictor activity before and after left ventricular assist device implantation in patients with end-stage heart failure.
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2344.
    >> Share

  6. BARTKO PE, Kreidel F, von Bardeleben RS, Goliasch G, et al
    Mitral regurgitation tips the scales in acute or worsening heart failure.
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2343.
    >> Share

  7. MOURA B, Aimo A, Al-Mohammad A, Flammer A, et al
    Integration of imaging and circulating biomarkers in heart failure: a Consensus Document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2021 Sep 5. doi: 10.1002/ejhf.2339.
    >> Share

  8. BECHER PM, Schrage B, Benson L, Fudim M, et al
    Phenotyping Heart Failure Patients for Iron Deficiency and Use of Intravenous Iron Therapy: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2021 Sep 3. doi: 10.1002/ejhf.2338.
    >> Share


  9. Abstracts of the Heart Failure 2021 and the World Congress on Acute Heart Failure, 29 June - 1 July 2021, Online Congress.
    Eur J Heart Fail. 2021;23 Suppl 2:2-322.
    >> Share

    August 2021
  10. CARBONE S, DaSilva-deAbreu A, Lavie CJ
    The SGLT2 Inhibitor Dapagliflozin Improves Prognosis in Systolic Heart Failure Independent of the Obesity Paradox.
    Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2336.
    >> Share

  11. DANDEL M, Hetzer R
    Benefits of Transvenous Mitral Annuloplasty in Heart Failure with Lower Degrees of Functional Mitral Regurgitation. Letter regarding the article ' Treating symptoms and reversing remodeling: clinical and echocardiographic 1-year outcomes with percutan
    Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2335.
    >> Share

  12. PUGLIESE NR, Paneni F, Mazzola M, De Biase N, et al
    Impact of epicardial adipose tissue on cardiovascular hemodynamics, metabolic profile, and prognosis in heart failure.
    Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2337.
    >> Share

  13. RICHARDS AM, Pemberton CJ
    Progress in proteomic probing for pathogenic pathways in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021 Aug 18. doi: 10.1002/ejhf.2332.
    >> Share

  14. STEWART COATS A
    Figures of the Heart Failure Association: Professor Dr. Wilfried Mullens, Board Member, 2018-2022, Coordinator of Study Group of Cardiorenal Dysfunction and Co-coordinator of Committee on Cardiac Devices.
    Eur J Heart Fail. 2021 Aug 9. doi: 10.1002/ejhf.2325.
    >> Share

  15. STEWART COATS AJ
    Figures of the Heart Failure Association: Loreena Hill (HFA Board Member and Nurse representative 2016-2020, and HFA Secretary 2020-2022).
    Eur J Heart Fail. 2021 Aug 6. doi: 10.1002/ejhf.2323.
    >> Share

  16. STEWART COATS AJ
    The HFA further develops it educational engagement working together on an MSc in Heart Failure with St George's Hospital in London.
    Eur J Heart Fail. 2021 Aug 6. doi: 10.1002/ejhf.2324.
    >> Share

    July 2021
  17. SKAARUP KG, Lassen MCH, Johansen ND, Sengelov M, et al
    Layer-Specific Global Longitudinal Strain and the Risk of Heart Failure and Cardiovascular Mortality in the General Population: The Copenhagen City Heart Study.
    Eur J Heart Fail. 2021 Jul 29. doi: 10.1002/ejhf.2315.
    >> Share

  18. PANDEY A, Butler J
    Improving Exercise Tolerance & Quality of Life in Heart Failure with Preserved Ejection Fraction Time to Think Outside the Heart.
    Eur J Heart Fail. 2021 Jul 22. doi: 10.1002/ejhf.2313.
    >> Share

  19. KHAN MS, Butler J, Greene SJ
    Simultaneous or Rapid Sequence Initiation of Medical Therapies for Heart Failure: Seeking to Avoid the Case of "Too Little, Too Late".
    Eur J Heart Fail. 2021 Jul 19. doi: 10.1002/ejhf.2311.
    >> Share

  20. SWEDBERG K
    The clinical practise of treating patients with chronic heart failure needs to be improved.
    Eur J Heart Fail. 2021 Jul 17. doi: 10.1002/ejhf.2309.
    >> Share

  21. ADAMSON C, Jhund PS, Docherty KF, Belohlavek J, et al
    Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.
    Eur J Heart Fail. 2021 Jul 16. doi: 10.1002/ejhf.2308.
    >> Share

  22. MILLER RJ, Howlett JG
    Untying the Gordian Knot of Sex and Heart Failure Therapy.
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2299.
    >> Share

  23. SAVARESE G, Merlo M, Coats AJ, Metra M, et al
    Best of European Journal of Heart Failure at the ESC/HFA Heart Failure Congress 2021.
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2306.
    >> Share

  24. ANKER MS, Tschope C
    Reply to 'Heart failure with preserved ejection fraction and COVID-19: which comes first, the chicken or the egg?'
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2305.
    >> Share

  25. GRAHAM FJ, Pellicori P, Cleland JGF, Clark AL, et al
    REPLY to a letter regarding the article "Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure".
    Eur J Heart Fail. 2021 Jul 14. doi: 10.1002/ejhf.2304.
    >> Share

  26. GREENE SJ, Butler J, Metra M
    Another Reason to Embrace Quadruple Medical Therapy for Heart Failure: Medications Enabling Tolerance of the Others.
    Eur J Heart Fail. 2021 Jul 14. doi: 10.1002/ejhf.2301.
    >> Share

  27. NUNEZ J, de la Espriella R, Minana G, Santas E, et al
    Antigen Carbohydrate 125 as a Biomarker in Heart Failure: a Narrative Review.
    Eur J Heart Fail. 2021 Jul 9. doi: 10.1002/ejhf.2295.
    >> Share

  28. KRESOJA KP, Rommel KP, Wachter R, Henger S, et al
    Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2291.
    >> Share

  29. BAYES-GENIS A, Januzzi JL, Richards AM, Arfsten H, et al
    The "Peptide for Life" Initiative: A Call for Action to Provide Equal Access for the Use of Natriuretic Peptides in the Diagnosis of Acute Heart Failure across Europe.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2293.
    >> Share

  30. BISSON A, Ding WY, Bodin A, Lip GYH, et al
    Clinical outcomes with digoxin vs beta-blocker for heart rate control in permanent atrial fibrillation with heart failure.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2292.
    >> Share

  31. CARAVITA S, Iacovoni A, Senni M
    The right side of the circulation in not secondary heart failure with preserved ejection fraction: an elephant in the room?
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2294.
    >> Share

  32. TOMASONI D, Adamo M, Metra M
    July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy.
    Eur J Heart Fail. 2021;23:1059-1061.
    >> Share

  33. MEHRA MR, Crandall DL, Gustafsson F, Jorde UP, et al
    Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial.
    Eur J Heart Fail. 2021;23:1226-1237.
    >> Share

  34. TURNER JM, Cox ZL, Testani JM
    Improving renal function during diuresis: useful information or just noise?
    Eur J Heart Fail. 2021;23:1131-1133.
    >> Share

  35. AMMIRATI E, Varrenti M, Veronese G, Fanti D, et al
    Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab.
    Eur J Heart Fail. 2021;23:1242-1245.
    >> Share

  36. PELLICORI P, Fitchett D, Kosiborod MN, Ofstad AP, et al
    Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.
    Eur J Heart Fail. 2021;23:1085-1093.
    >> Share

  37. KUSCHYK J, Falk P, Demming T, Marx O, et al
    Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system.
    Eur J Heart Fail. 2021;23:1160-1169.
    >> Share

  38. DENIAU B, Picod A, Azibani F, Gayat E, et al
    The CLIP-based mortality score in cardiogenic shock: suitable only for cardiogenic shock?
    Eur J Heart Fail. 2021;23:1240-1242.
    >> Share

  39. ZYMLINSKI R, Biegus J, Ponikowski P
    Not all fluid overloads are the same: some practical considerations for better decongestion.
    Eur J Heart Fail. 2021;23:1106-1109.
    >> Share

  40. KARAMICHALAKIS N, Ikonomidis I, Parissis J, Simitsis P, et al
    Association of ventricular-arterial interaction with the response to cardiac resynchronization therapy.
    Eur J Heart Fail. 2021;23:1238-1240.
    >> Share

  41. FINOCCHIARO G, Sinagra G, Papadakis M, Carr-White G, et al
    The labyrinth of nomenclature in Cardiology. Eternal dilemmas and new challenges on the horizon in the personalized medicine era.
    Eur J Heart Fail. 2021;23:1062-1067.
    >> Share

    June 2021
  42. PONIKOWSKI P, Alemayehu W, Oto A, Bahit MC, et al
    Vericiguat in Patients with Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA trial.
    Eur J Heart Fail. 2021 Jun 30. doi: 10.1002/ejhf.2285.
    >> Share

  43. MCEWAN P, Ponikowski P, Davis JA, Rosano G, et al
    Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.
    Eur J Heart Fail. 2021 Jun 30. doi: 10.1002/ejhf.2270.
    >> Share

  44. YAFASOVA A, Butt JH, Rorth R
    Troponin - An important prognostic biomarker in patients with heart failure and reduced ejection fraction?
    Eur J Heart Fail. 2021 Jun 29. doi: 10.1002/ejhf.2282.
    >> Share

  45. GREENE SJ, Fonarow GC
    Clinical Inertia and Medical Therapy for Heart Failure: The Unintended Harms of "First, Do No Harm".
    Eur J Heart Fail. 2021 Jun 29. doi: 10.1002/ejhf.2283.
    >> Share

  46. ABDIN A, Bohm M
    Renal function and vericiguat in heart failure patients: Light at the end of the tunnel!
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2280.
    >> Share

  47. KHAN MS, Khan F, Fonarow GC, Sreenivasan J, et al
    Dietary Interventions and Nutritional Supplements for Heart Failure: A Systematic Appraisal and Evidence Map.
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2278.
    >> Share

  48. ANKER SD, Khan MS, Shahid I, Filippatos G, et al
    SGLT-2 Inhibitors in Heart Failure with Preserved Ejection Fraction Reasons for Optimism.
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2279.
    >> Share

  49. SHAH SJ, Cowie MR, Wachter R, Szecsody P, et al
    Baseline Characteristics of Patients in the PARALLAX Trial: Insights into Quality of Life and Exercise Capacity in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jun 25. doi: 10.1002/ejhf.2277.
    >> Share

  50. PAGNESI M, Adamo M, Sama IE, Anker SD, et al
    Impact of mitral regurgitation in patients with worsening heart failure: Insights from BIOSTAT-CHF.
    Eur J Heart Fail. 2021 Jun 23. doi: 10.1002/ejhf.2276.
    >> Share

  51. BARATTO C, Caravita S, Parati G
    HFpEF and COVID-19: which comes first, the chicken or the egg? Letter regarding the article "Heart Failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings".
    Eur J Heart Fail. 2021 Jun 17. doi: 10.1002/ejhf.2273.
    >> Share

  52. SAVARESE G, Bodegard J, Norhammar A, Sartipy P, et al
    Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
    Eur J Heart Fail. 2021 Jun 15. doi: 10.1002/ejhf.2271.
    >> Share

  53. RICHARDS AM, Pemberton CJ
    Urinary Peptides in Heart Failure - the need for care with pees and cues.
    Eur J Heart Fail. 2021 Jun 12. doi: 10.1002/ejhf.2269.
    >> Share

  54. PATEL RB, Shah SJ
    The Splanchnic Reservoir: An Oasis for Blood Volume in Heart Failure with Preserved Ejection Fraction?
    Eur J Heart Fail. 2021 Jun 12. doi: 10.1002/ejhf.2268.
    >> Share

  55. STOLFO D, Savarese G
    Association Between Heart Failure and Cancer: Is Gender the Answer?
    Eur J Heart Fail. 2021 Jun 11. doi: 10.1002/ejhf.2261.
    >> Share

  56. BHATT AS, Vaduganathan M, Claggett BL, Liu J, et al
    Effect of Sacubitril/Valsartan versus Enalapril on Changes in Heart Failure Therapies Over Time: The PARADIGM-HF Trial.
    Eur J Heart Fail. 2021 Jun 7. doi: 10.1002/ejhf.2259.
    >> Share

  57. TOMASONI D, Adamo M, Metra M
    June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment.
    Eur J Heart Fail. 2021;23:847-849.
    >> Share

  58. SEGAR MW, Pandey A
    Omics, machine learning, and personalized medicine in heart failure with preserved ejection fraction: promising future or false hope?
    Eur J Heart Fail. 2021;23:992-994.
    >> Share

  59. FERREIRA JP
    Circulating levels of procollagen type I carboxy-terminal propeptide reflect myocardial fibrosis.
    Eur J Heart Fail. 2021;23:945-946.
    >> Share

  60. RAAFS AG, Verdonschot JAJ, Henkens MTHM, Adriaans BP, et al
    The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy - A multilevel assessment o
    Eur J Heart Fail. 2021;23:933-944.
    >> Share

  61. GARCIA-PAVIA P, Bengel F, Brito D, Damy T, et al
    Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy.
    Eur J Heart Fail. 2021;23:895-905.
    >> Share

  62. HAVERKAMP W, Butler J, Anker SD
    Can we trust a smartwatch ECG? Potential and limitations.
    Eur J Heart Fail. 2021;23:850-853.
    >> Share

  63. SATTAR N, Januzzi JL
    Can biomarkers help find the 'sweet spot' for treating patients with diabetes?
    Eur J Heart Fail. 2021;23:1037-1039.
    >> Share

  64. PARCHA V, Arora P
    Sodium-glucose co-transporter 2 inhibitors: strength of evidence for a cardio-renal-metabolic therapy.
    Eur J Heart Fail. 2021;23:1009-1011.
    >> Share

  65. GREENBERG B, Adler E, Campagnari C, Yagil A, et al
    A machine learning risk score predicts mortality across the spectrum of left ventricular ejection fraction.
    Eur J Heart Fail. 2021;23:995-999.
    >> Share

  66. DAMY T, Sultan MB, Witteles R
    Reply to the letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
    Eur J Heart Fail. 2021;23:1057-1058.
    >> Share

    May 2021
  67. PACKER M, Januzzi JL Jr, Ferreira JP, Anker SD, et al
    Concentration-Dependent Clinical and Prognostic Importance of High-Sensitivity Cardiac Troponin T in Heart Failure and a Reduced Ejection Fraction and the Influence of Empagliflozin: the EMPEROR-Reduced Trial.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2256.
    >> Share

  68. BUTLER J, Yang M, Sawhney B, Chakladar S, et al
    Treatment Patterns and Clinical Outcomes Among Patients <65 Years with a Worsening Heart Failure Event.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2252.
    >> Share

  69. SORIMACHI H, Burkhoff D, Verbrugge FH, Omote K, et al
    Obesity, Venous Capacitance, and Venous Compliance in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2254.
    >> Share

  70. SOLOMON SD, de Boer RA, DeMets D, Hernandez AF, et al
    Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
    Eur J Heart Fail. 2021 May 29. doi: 10.1002/ejhf.2249.
    >> Share

  71. TKACZYSZYN M, Comin-Colet J, Voors AA, van Veldhuisen DJ, et al
    Iron deficiency contributes to the resistance to endogenous erythropoietin in anaemic heart failure patients.
    Eur J Heart Fail. 2021 May 29. doi: 10.1002/ejhf.2253.
    >> Share

  72. GRAHAM FJ, Masini G, Pellicori P, Cleland JGF, et al
    Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure.
    Eur J Heart Fail. 2021 May 28. doi: 10.1002/ejhf.2251.
    >> Share

  73. FADINI GP, Avogaro A
    A simple way to spotlight hidden heart failure in type 2 diabetes?
    Eur J Heart Fail. 2021 May 28. doi: 10.1002/ejhf.2258.
    >> Share

  74. VAN SPALL HG, Averbuch T, Damman K, Voors AA, et al
    Risk and Risk Reduction In Trials of Heart Failure with Reduced Ejection Fraction: Absolute or Relative?
    Eur J Heart Fail. 2021 May 26. doi: 10.1002/ejhf.2248.
    >> Share

  75. SEFEROVIC PM, Tsutsui H, McNamara DM, Ristic AD, et al
    Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy.
    Eur J Heart Fail. 2021 May 19. doi: 10.1002/ejhf.2190.
    >> Share

  76. VOORS AA, Mulder H, Reyes E, Cowie MR, et al
    Renal Function and the Effects of Vericiguat in Patients with Worsening Heart Failure with Reduced Ejection Fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF) Trial.
    Eur J Heart Fail. 2021 May 17. doi: 10.1002/ejhf.2221.
    >> Share

  77. BRAUNWALD E
    The War on Heart Failure.
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2217.
    >> Share

  78. KAPELIOS CJ, Canepa M, Savarese G, Lund LH, et al
    Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle "do no harm"?
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2218.
    >> Share

  79. BISTOLA V, Simitsis P, Parissis J, Ouwerkerk W, et al
    Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum.
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2219.
    >> Share

  80. KAPELIOS CJ, Canepa M, Savarese G, Lund LH, et al
    Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle "do no harm"?
    Eur J Heart Fail. 2021 May 8. doi: 10.1002/ejhf.2214.
    >> Share

  81. TOCCHETTI CG, Mercurio V, Maack C
    The multifaceted mechanisms of nitroxyl in heart failure: Inodilator or "only" vasodilator?
    Eur J Heart Fail. 2021 May 2. doi: 10.1002/ejhf.2204.
    >> Share

  82. HILL L, Lambrinou E, Antoniou S
    Optimizing evidence-based heart failure medication: Every contact counts.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2213.
    >> Share

  83. ROSANO GMC, Moura B, Metra M, Bauersachs J, et al
    Patients profiling in Heart Failure for tailoring medical therapy A consensus document of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2206.
    >> Share

  84. LEEDY DJ, Reding KW, Vasbinder AL, Anderson GL, et al
    The association between heart failure and incident cancer in women: An analysis of the Women's Health Initiative.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2207.
    >> Share

  85. MALEK F, Gajewski P, Zymlinski R, Janczak D, et al
    Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: First-in-human clinical trial.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2209.
    >> Share

  86. MULDER BA, van Veldhuisen DJ, Rienstra M
    Sudden cardiac death in heart failure: more than meets the eye.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2212.
    >> Share

  87. HADZIBEGOVIC S, Lena A, Churchill TW, Ho JE, et al
    Heart Failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2210.
    >> Share

  88. TOMASONI D, Adamo M, Metra M
    May 2021 at a glance: focus on acute heart failure and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021;23:691-692.
    >> Share

  89. MULLENS W, Martens P, Witte K, Cowie MR, et al
    Reply to 'Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy'.
    Eur J Heart Fail. 2021;23:844-845.
    >> Share

  90. TOMASONI D, Coats AJS
    The Altmetric Attention Score: how science tries to meet social media.
    Eur J Heart Fail. 2021;23:693-697.
    >> Share

  91. SUGUMAR H, Nanayakkara S, Vizi D, Wright L, et al
    A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF.
    Eur J Heart Fail. 2021;23:785-796.
    >> Share

  92. KHEDRAKI R, Tang WHW
    Identifying sodium non-excretors: heart failure's emerging golden ticket for risk stratification.
    Eur J Heart Fail. 2021;23:740-742.
    >> Share

  93. VEENIS JF, Brugts JJ, Yalcin YC, Caliskan K, et al
    Reply to 'Aortic valve surgery and left ventricular assist device: lights and shadows'.
    Eur J Heart Fail. 2021;23:842-843.
    >> Share

  94. LOARDI C, Zanobini M
    Aortic valve surgery and left ventricular assist device: lights and shadows. Letter regarding the article 'Survival following a concomitant aortic valve procedure during left ventricular assist device surgery: an ISHLT Mechanically Assisted Circulator
    Eur J Heart Fail. 2021;23:841-842.
    >> Share

  95. BHATT AS, Yanamandala M, Konstam MA
    For vaptans, as for life, balance is better.
    Eur J Heart Fail. 2021;23:751-753.
    >> Share

  96. SANDERS-VAN WIJK S, Barandiaran Aizpurua A, Brunner-La Rocca HP, Henkens MTHM, et al
    The HFA-PEFF and H2 FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021;23:838-840.
    >> Share

    April 2021
  97. FRASER AG, Tschope C, de Boer RA
    Diagnostic recommendations and phenotyping for heart failure with preserved ejection fraction - knowing more and understanding less?
    Eur J Heart Fail. 2021 Apr 30. doi: 10.1002/ejhf.2205.
    >> Share

  98. BEUSEKAMP JC, Tromp J, Boorsma EM, Heerspink HJL, et al
    Effects of SGLT2 inhibition with Empagliflozin on Potassium Handling in Patients with Acute Heart Failure.
    Eur J Heart Fail. 2021 Apr 26. doi: 10.1002/ejhf.2197.
    >> Share

  99. FUDIM M, Ponikowski P, Burkhoff D, Dunlap M, et al
    Splanchnic Nerve Modulation in Heart Failure: Mechanistic Overview, Initial Clinical Experience, and Safety Considerations.
    Eur J Heart Fail. 2021 Apr 22. doi: 10.1002/ejhf.2196.
    >> Share

  100. HE T, Mischak M, Clark AL, Campbell RT, et al
    Urinary peptides in heart failure: a link to molecular pathophysiology.
    Eur J Heart Fail. 2021 Apr 21. doi: 10.1002/ejhf.2195.
    >> Share

  101. FINE NM, Howlett JG
    Cautious optimism for machine learning techniques for prediction of heart failure outcomes.
    Eur J Heart Fail. 2021 Apr 20. doi: 10.1002/ejhf.2192.
    >> Share

  102. NASSIF M, Butler J
    Moving in the Right Direction but Not There Yet. The Utility, Measurement, and Analysis of Health Status in Heart Failure Trials.
    Eur J Heart Fail. 2021 Apr 20. doi: 10.1002/ejhf.2193.
    >> Share

  103. JERING KS, Claggett B, Pfeffer MA, Granger C, et al
    Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics.
    Eur J Heart Fail. 2021 Apr 12. doi: 10.1002/ejhf.2191.
    >> Share

  104. BAYES-GENIS A, Lupon J
    Heart failure is ejection fraction in motion.
    Eur J Heart Fail. 2021 Apr 9. doi: 10.1002/ejhf.2185.
    >> Share

  105. ABRAHAM WT
    Interatrial Shunting for the Treatment of Heart Failure: An On-Demand, Self-Regulating Left Atrial Pressure Lowering System.
    Eur J Heart Fail. 2021 Apr 8. doi: 10.1002/ejhf.2184.
    >> Share

  106. SORENSEN TB, Minamisawa M, Liu J, Claggett B, et al
    The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (COSMIC -HF).
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2181.
    >> Share

  107. FERREIRA JP
    Cognitive function assessment for personalized heart failure disease management programmes.
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2183.
    >> Share

  108. GIRERD N, Felker GM
    The lower is not always the better: a better understanding of loop diuretics in heart failure.
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2182.
    >> Share

  109. BOLLI R, Mitrani RD, Hare JM, Pepine CJ, et al
    A Phase II Study of Autologous Mesenchymal Stromal Cells and c-kit Positive Cardiac Cells, Alone or in Combination, in Patients with Ischemic Heart Failure: The CCTRN CONCERT-HF Trial.
    Eur J Heart Fail. 2021 Apr 3. doi: 10.1002/ejhf.2178.
    >> Share

  110. PAGNESI M, Adamo M, Metra M
    April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure.
    Eur J Heart Fail. 2021;23:505-506.
    >> Share

  111. BAYES-GENIS A
    The CONCERT-HF trial: a sweet and sour symphony.
    Eur J Heart Fail. 2021;23:675-676.
    >> Share

  112. GARCIA-PAVIA P, Rapezzi C, Adler Y, Arad M, et al
    Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
    Eur J Heart Fail. 2021;23:512-526.
    >> Share

  113. BOUDOULAS KD, Boudoulas H
    Time and left ventricular function: the forgotten dynamic factor.
    Eur J Heart Fail. 2021;23:552-554.
    >> Share

  114. STRANGE G, Playford D, Scalia GM, Celermajer DS, et al
    Change in ejection fraction and long-term mortality in adults referred for echocardiography.
    Eur J Heart Fail. 2021;23:555-563.
    >> Share

  115. COATS AJS, Rosano G
    Treatments delayed lead to lives lost.
    Eur J Heart Fail. 2021;23:511.
    >> Share

  116. DOCHERTY KF, Curtain JP, Anand IS, Bengtsson O, et al
    Effect of dapagliflozin on anaemia in DAPA-HF.
    Eur J Heart Fail. 2021;23:617-628.
    >> Share

  117. DOBNER S
    Letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
    Eur J Heart Fail. 2021;23:681-682.
    >> Share

  118. HAGNAS MJ, Grasso C, Di Salvo ME, Sardone A, et al
    Effect of post-procedural evidence-based therapy on 2-year prognosis after transcatheter mitral valve repair.
    Eur J Heart Fail. 2021;23:677-679.
    >> Share

    March 2021
  119. WETTERSTEN N, Horiuchi Y, van Veldhuisen DJ, Ix JH, et al
    Decongestion Discriminates Risk for One Year Mortality in Patients with Improving Renal Function in Acute Heart Failure.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2179.
    >> Share

  120. HUYNH QL, Whitmore K, Negishi K, DePasquale CG, et al
    Cognitive Impairment as a Determinant of Response to Management Plans After Heart Failure Admission.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2177.
    >> Share

  121. BARAKAT MF, Amin-Youseff G, Okonko DO
    Oral Sucrosomial Iron in Heart Failure with a Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2176.
    >> Share

  122. UIJL A, Savarese G, Vaartjes I, Dahlstrom U, et al
    Identification of Distinct Phenotypic Clusters in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2169.
    >> Share

  123. KALOGEROPOULOS AP, Hotelling J, Skopicki HA
    Blood Counts: Targeting Anemia in Patients with Heart Failure.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2173.
    >> Share

  124. KHAN MS, Fonarow GC, Greene SJ
    SGLT-2 Inhibitors for Heart Failure: Clinical Trial Efficacy and Clinical Practice Effectiveness.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2170.
    >> Share

  125. WAN SH, Pandey A
    Targeting the nitrate-nitrite-nitric oxide pathway in heart failure with preserved ejection fraction: too soon to say no to nitric oxide?
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2171.
    >> Share

  126. KHAN MS, Usman MS, Butler J
    Etiology Of Heart Failure Is In The Eye Of The Beholder: Does It Even Matter?
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2166.
    >> Share

  127. PACKER M
    What Causes Exertional Dyspnea in Patients With Atrial Fibrillation? Implications for Catheter Ablation in Patients With Heart Failure.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2164.
    >> Share

  128. BHATT AS, Varshney AS, Nekoui M, Moscone A, et al
    Virtual Optimization of Guideline-Directed Medical Therapy in Hospitalized Patients with Heart Failure with Reduced Ejection Fraction: the IMPLEMENT-HF Pilot Study.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2163.
    >> Share

  129. METRA M, Coats AJS
    Why we love heart failure. An introduction to the universal definition of heart failure.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2168.
    >> Share

  130. GUPTA P, Voors AA, Patel P, Lane D, et al
    Non-adherence to heart failure medications predicts clinical outcomes: Assessment in a single spot urine sample by liquid chromatography - tandem mass spectrometry (results of a prospective multicentre study).
    Eur J Heart Fail. 2021 Mar 23. doi: 10.1002/ejhf.2160.
    >> Share

  131. CHIONCEL O, Stewart Coats AJ
    National Heart Failure Societies Summit 2020.
    Eur J Heart Fail. 2021 Mar 21. doi: 10.1002/ejhf.2157.
    >> Share

  132. BOORSMA EM, Ter Maaten JM, Damman K, van Veldhuisen DJ, et al
    Dipeptidyl peptidase-3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure.
    Eur J Heart Fail. 2021 Mar 20. doi: 10.1002/ejhf.2158.
    >> Share

  133. RAVERA A, Santema BT, Sama IE, Meyer S, et al
    Quality of life in men and women with heart failure: association with outcome, and comparison of the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire.
    Eur J Heart Fail. 2021 Mar 16. doi: 10.1002/ejhf.2154.
    >> Share

  134. TROMP J, Bryant JA, Jin X, van Woerden G, et al
    Epicardial fat in heart failure with reduced versus preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 16. doi: 10.1002/ejhf.2156.
    >> Share

  135. ZIAEIAN B, Fonarow GC
    Making heart failure count.
    Eur J Heart Fail. 2021 Mar 13. doi: 10.1002/ejhf.2148.
    >> Share

  136. PACKER M, McMurray JJV
    Rapid Evidence-Based Sequencing of Foundational Drugs for Heart Failure and a Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 11. doi: 10.1002/ejhf.2149.
    >> Share

  137. PUVREZ A, Duchenne J, Gorcsan J 3rd, Marwick TH, et al
    Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy. Letter regarding the article 'Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position s
    Eur J Heart Fail. 2021 Mar 11. doi: 10.1002/ejhf.2150.
    >> Share

  138. WOLSK E, Kaye DM, Komtebedde J, Shah SJ, et al
    Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 8. doi: 10.1002/ejhf.2146.
    >> Share

  139. WOOLLEY RJ, Ceelen D, Ouwerkerk W, Tromp J, et al
    Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 2. doi: 10.1002/ejhf.2144.
    >> Share

  140. CARAVITA S, Senni M, Parati G
    Reply to: 'The hyperdynamic circulatory profile of patients with COVID-19-related acute vascular distress syndrome'.
    Eur J Heart Fail. 2021;23:493-494.
    >> Share

  141. TOMASONI D, Petrie MC, Adamo M, Metra M, et al
    Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy.
    Eur J Heart Fail. 2021;23:486-488.
    >> Share

  142. MAHJOUB Y, Rodenstein DO, Jounieaux V
    The hyperdynamic circulatory profile of patients with COVID-19-related acute vascular distress syndrome. Letter regarding the article 'Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical vent
    Eur J Heart Fail. 2021;23:493.
    >> Share

  143. PAGNESI M, Adamo M, Metra M
    March 2021 at a glance: focus on epidemiology, prevention and COVID-19.
    Eur J Heart Fail. 2021;23:347-349.
    >> Share

  144. CARO-CODON J, Rey JR, Buno A, Iniesta AM, et al
    Characterization of NT-proBNP in a large cohort of COVID-19 patients.
    Eur J Heart Fail. 2021;23:456-464.
    >> Share

  145. GARG A, Seeliger B, Derda AA, Xiao K, et al
    Circulating cardiovascular microRNAs in critically ill COVID-19 patients.
    Eur J Heart Fail. 2021;23:468-475.
    >> Share

  146. SAVARESE G, Benson L, Sundstrom J, Lund LH, et al
    Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.
    Eur J Heart Fail. 2021;23:476-485.
    >> Share

  147. BRAUNWALD E, Antman EM
    The path to universality.
    Eur J Heart Fail. 2021;23:381-383.
    >> Share

  148. OLSEN FJ, Solomon SD, Biering-Sorensen T
    Piecing together the puzzle of sex-specific differences in left ventricular ejection fraction.
    Eur J Heart Fail. 2021;23:417-419.
    >> Share

  149. CHESSA M, Tutarel O
    Adults with congenital heart disease - we need more Europe for a better care.
    Eur J Heart Fail. 2021;23:454-455.
    >> Share

  150. STEWART S, Playford D, Scalia GM, Currie P, et al
    Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men.
    Eur J Heart Fail. 2021;23:406-416.
    >> Share

  151. BRIDA M, Simkova I, Jovovic L, Prokselj K, et al
    European Society of Cardiology Working Group on Adult Congenital Heart Disease and Study Group for Adult Congenital Heart Care in Central and South Eastern European Countries consensus paper: current status, provision gaps and investment required.
    Eur J Heart Fail. 2021;23:445-453.
    >> Share

  152. SPERRY BW, Tang Y, Jones PG, Spertus JA, et al
    Cumulative events in the TOPCAT trial.
    Eur J Heart Fail. 2021;23:491-492.
    >> Share

  153. ITO M, Matsue Y, Minamino T
    Worsening renal function during intensive blood pressure control: another example of not prognostically relevant creatinine rise?
    Eur J Heart Fail. 2021;23:393-395.
    >> Share

    February 2021
  154. DAUW J, Martens P, Tersalvi G, Schouteden J, et al
    Diuretic Response and Effects of Diuretic Omission in Ambulatory Heart Failure Patients on Chronic Low Dose Loop Diuretic Therapy.
    Eur J Heart Fail. 2021 Feb 28. doi: 10.1002/ejhf.2145.
    >> Share

  155. PASCUAL-FIGAL DA
    Biochemical or clinical heart failure, not so simple.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2128.
    >> Share

  156. SEFEROVIC PM, Vardas P, Jankowska EA, Maggioni AP, et al
    The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2143.
    >> Share

  157. VERBRUGGE FH, Reddy YNV, Sorimachi H, Omote K, et al
    Diagnostic Scores Predict Morbidity and Mortality in Patients Hospitalised for Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2142.
    >> Share

  158. TURGEON RD, Barry AR, Hawkins NM, Ellis UM, et al
    Pharmacotherapy for Heart Failure with Reduced Ejection Fraction and Health-Related Quality of Life: Systematic Review and Meta-Analysis.
    Eur J Heart Fail. 2021 Feb 25. doi: 10.1002/ejhf.2141.
    >> Share

  159. LANG NN, Ahmad FA, Cleland JG, O'Connor CM, et al
    Hemodynamic Effects of the Nitroxyl Donor Cimlanod (BMS-986231) in Chronic Heart Failure: A Randomized Trial.
    Eur J Heart Fail. 2021 Feb 23. doi: 10.1002/ejhf.2138.
    >> Share

  160. TROMP J, Ponikowski P, Salsali A, Angermann CE, et al
    SGLT2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2137.
    >> Share

  161. BHATIA K, Jain V, Gupta K, Bansal A, et al
    Prevention of Heart Failure Events with SGLT-2 Inhibitors Across a Spectrum of Cardio-Renal-Metabolic Risk.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2135.
    >> Share

  162. SLIWA K, van der Meer P, Petrie MC, Frogoudaki A, et al
    Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripar
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2133.
    >> Share

  163. FERREIRA JP, Claggett BL, Liu J, Desai AS, et al
    Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2134.
    >> Share

  164. BOZKURT B, Coats A, Tsutsui H
    A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure Consensus Conference.
    Eur J Heart Fail. 2021 Feb 19. doi: 10.1002/ejhf.2115.
    >> Share

  165. CHIONCEL O, Ambrosy AP, Maggioni AP
    Temporal Trends in the Outcomes of Acute Heart Failure: Between Consolatory Evidences and Real Progress.
    Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2130.
    >> Share

  166. BECHER PM, Schrage B, Ferrannini G, Benson L, et al
    Use of Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure and Type 2 Diabetes Mellitus: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2131.
    >> Share

  167. BUTT JH, Nicolau JC, Verma S, Docherty KF, et al
    Efficacy and Safety of Dapagliflozin According to Aetiology in Heart Failure with Reduced Ejection Fraction: Insights from the DAPA-HF trial.
    Eur J Heart Fail. 2021 Feb 16. doi: 10.1002/ejhf.2124.
    >> Share

  168. RICHARDS AM
    Cardiac Myosin-Binding Protein C as a candidate biomarker in Heart Failure: rational but not revolutionary.
    Eur J Heart Fail. 2021 Feb 15. doi: 10.1002/ejhf.2126.
    >> Share

  169. ALHAKAK AS, Teerlink JR, Lindenfeld J, Bohm M, et al
    The Significance of Left Ventricular Ejection Time in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Feb 15. doi: 10.1002/ejhf.2125.
    >> Share

  170. MILLER WL, Sorimachi H, Grill DE, Fischer K, et al
    Contributions of Cardiac Dysfunction and Volume Status to Central Hemodynamics in Chronic Heart Failure.
    Eur J Heart Fail. 2021 Feb 9. doi: 10.1002/ejhf.2121.
    >> Share

  171. ROHDE LE, Vaduganathan M, Claggett BL, Polanczyk CA, et al
    Dynamic Changes in Cardiovascular and Systemic Variables Prior to Sudden Cardiac Death in Heart Failure with Reduced Ejection Fraction: a PARADIGM-HF Analysis.
    Eur J Heart Fail. 2021 Feb 9. doi: 10.1002/ejhf.2120.
    >> Share

  172. VOLTERRANI M, Perrone V, Degli Esposti L
    Reply letter regarding the article "Effects of hyperkalemia and non-adherence to renin angiotensin aldosterone system inhibitors (RAASi) in patients affected by heart failure in Italy: a propensity-matched study".
    Eur J Heart Fail. 2021 Feb 8. doi: 10.1002/ejhf.2123.
    >> Share

  173. PAITAZOGLOU C, Bergmann MW, Ozdemir R, Pfister R, et al
    One-year results of the first-in-man study investigating the Atrial-Flow-Regulator for left-atrial shunting in symptomatic heart failure patients: the PRELIEVE study.
    Eur J Heart Fail. 2021 Feb 8. doi: 10.1002/ejhf.2119.
    >> Share

  174. COTTER G, Davison BA, Edwards C, Takagi K, et al
    Acute Heart Failure Treatment - A Light at The End of the Tunnel?
    Eur J Heart Fail. 2021 Feb 6. doi: 10.1002/ejhf.2116.
    >> Share

  175. CLERICO A, Aimo A, Passino C
    The pathophysiological and clinical relevance of combined measurement of natriuretic peptides and cardiac troponins for risk prediction of incident heart failure in community-dwelling individuals.
    Eur J Heart Fail. 2021 Feb 2. doi: 10.1002/ejhf.2112.
    >> Share


  176. Corrigendum to 'Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology' [Eur J Heart Fail 2020;22:1315-1341].
    Eur J Heart Fail. 2021;23:345.
    >> Share


  177. Corrigendum to 'Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncolog
    Eur J Heart Fail. 2021;23:345.
    >> Share

  178. SMITH N, Tampakakis E
    COVID-19 acute respiratory distress syndrome: intriguing haemodynamics of an intriguing syndrome.
    Eur J Heart Fail. 2021;23:208-210.
    >> Share

  179. PAGNESI M, Adamo M, Metra M
    February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy.
    Eur J Heart Fail. 2021;23:201-202.
    >> Share

  180. STOGIOS N, Fezza G, Wong JV, Ross HJ, et al
    Current challenges for using the Kansas City Cardiomyopathy Questionnaire to obtain a standardized patient-reported health status outcome.
    Eur J Heart Fail. 2021;23:205-207.
    >> Share

  181. ARNOLD SV, Butler J, Spertus JA
    Standardizing the standard: reporting health status in clinical trials.
    Eur J Heart Fail. 2021;23:203-204.
    >> Share

  182. CASTIGLIONE V, Franzini M, Aimo A, Carecci A, et al
    Use of biomarkers to diagnose and manage cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:217-230.
    >> Share

  183. PERLINI S, Mussinelli R, Salinaro F
    New effective treatment options reinforce disease awareness: the case of transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:290-292.
    >> Share

  184. LYLE MA, Cooper LT
    Failure of intravenous immunoglobulin to improve cardiac function in parvovirus B19-associated chronic dilated cardiomyopathy.
    Eur J Heart Fail. 2021;23:310-311.
    >> Share

  185. RAPEZZI C, Aimo A, Emdin M
    Tafamidis is entering the clinical arena for the treatment of transthyretin-related cardiomyopathy: certainties and unmet needs.
    Eur J Heart Fail. 2021;23:286-289.
    >> Share

  186. ASLEH R, Amir O, Kushwaha SS
    Dynamics of myocardial fibrosis after left ventricular assist device implantation: should speeding up the scar have us scared stiff?
    Eur J Heart Fail. 2021;23:335-338.
    >> Share

  187. HAZEBROEK MR, Henkens MTHM, Raafs AG, Verdonschot JAJ, et al
    Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial.
    Eur J Heart Fail. 2021;23:302-309.
    >> Share

  188. BONDERMAN D
    How to ATTR-ACT the perfect match?
    Eur J Heart Fail. 2021;23:275-276.
    >> Share

  189. RAPEZZI C, Giannini F, Campo G
    Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?
    Eur J Heart Fail. 2021;23:259-263.
    >> Share

  190. BEZARD M, Kharoubi M, Galat A, Poullot E, et al
    Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
    Eur J Heart Fail. 2021;23:264-274.
    >> Share

  191. DAMY T, Garcia-Pavia P, Hanna M, Judge DP, et al
    Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
    Eur J Heart Fail. 2021;23:277-285.
    >> Share

  192. NICOL M, Deney A, Lairez O, Vergaro G, et al
    Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:231-239.
    >> Share

  193. ROSENBLUM H, Masri A, Narotsky DL, Goldsmith J, et al
    Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:250-258.
    >> Share

  194. SINAGRA G, Porcari A, Gentile P, Artico J, et al
    Viral presence-guided immunomodulation in lymphocytic myocarditis: an update.
    Eur J Heart Fail. 2021;23:211-216.
    >> Share

    January 2021
  195. CANEPA M, Ameri P, Lainscak M
    COPD and comorbidities in heart failure: the next frontier of SGLT2 inhibitors?
    Eur J Heart Fail. 2021 Jan 27. doi: 10.1002/ejhf.2109.
    >> Share

  196. PETRIE MC, Lee MMY, Docherty KF
    Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?
    Eur J Heart Fail. 2021 Jan 27. doi: 10.1002/ejhf.2108.
    >> Share

  197. DOCHERTY KF, Vaduganathan M
    OUTSTEP-HF: re-evaluating the role of physical activity measures in drug and device development in heart failure.
    Eur J Heart Fail. 2021 Jan 22. doi: 10.1002/ejhf.2106.
    >> Share

  198. SUTHAHAR N, Meems LMG, Groothof D, Bakker SJL, et al
    Relationship between Body-Mass Index, Cardiovascular Biomarkers and Incident Heart Failure.
    Eur J Heart Fail. 2021 Jan 14. doi: 10.1002/ejhf.2102.
    >> Share

  199. KIMMOUN A, Takagi K, Gall E, Ishihara S, et al
    Temporal trends in mortality and readmission after acute heart failure: A systematic review and meta-regression in the past four decades.
    Eur J Heart Fail. 2021 Jan 14. doi: 10.1002/ejhf.2103.
    >> Share

  200. KOZHUHAROV N, Wussler D, Kaier T, Strebel I, et al
    Cardiac Myosin-Binding Protein C in the Diagnosis and Risk Stratification of Acute Heart Failure.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2094.
    >> Share

  201. REDDY YNV, Stewart GM, Obokata M, Koepp KE, et al
    Peripheral and Pulmonary Effects of Inorganic-Nitrite during Exercise in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2093.
    >> Share

  202. KARAVIDAS A, Troganis E, Lazaros G, Balta D, et al
    Oral Sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: A non-randomized, open-label, proof-of-concept study.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2092.
    >> Share

  203. TOMASONI D, Adamo M, Metra M
    January 2021 at a glance: focus on sex differences, acute heart failure and exercise capacity.
    Eur J Heart Fail. 2021;23:1-2.
    >> Share

  204. MULLENS W, Martens P
    Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic.
    Eur J Heart Fail. 2021;23:79-82.
    >> Share

  205. FARMAKIS D, Filippatos G
    Arrhythmias in cancer: rhythm is gonna get you!
    Eur J Heart Fail. 2021;23:154-156.
    >> Share

  206. ANKER MS, von Haehling S, Coats AJS, Riess H, et al
    Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study.
    Eur J Heart Fail. 2021;23:145-153.
    >> Share

  207. CHIONCEL O, Collins SP, Seferovic P
    Does end-organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The two-faced Janus. Reply.
    Eur J Heart Fail. 2021;23:197-198.
    >> Share

    December 2020
  208. PABEL S, Hamdani N, Sossalla S
    A mechanistic rationale for the investigation of SGLT2 inhibitors in HFpEF - Letter regarding the article 'Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial'.
    Eur J Heart Fail. 2020 Dec 29. doi: 10.1002/ejhf.2091.
    >> Share

  209. DEWAN P, Docherty KF, Bengtsson O, de Boer RA, et al
    Effects of dapagliflozin in heart failure with reduced ejection fraction, and COPD: An analysis of DAPA-HF.
    Eur J Heart Fail. 2020 Dec 23. doi: 10.1002/ejhf.2083.
    >> Share

  210. ASLAM MI, Jani V, Lin B, Dunkerly-Eyring B, et al
    Pulmonary Artery Pulsatility Index Predicts Right Ventricular Myofilament Dysfunction in Advanced Human Heart Failure.
    Eur J Heart Fail. 2020 Dec 21. doi: 10.1002/ejhf.2084.
    >> Share

  211. MORIYAMA H, Kohno T, Kohsaka S
    Letter regarding the article "Effects of hyperkalemia and non-adherence to renin angiotensin aldosterone system inhibitors (RAASi) in patients affected by heart failure in Italy: a propensity-matched study".
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2081.
    >> Share

  212. DAVISON BA, Senger S, Sama IE, Koch GG, et al
    Is Acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF.
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2077.
    >> Share

  213. SCHNEIDER B, Ong P
    Improving female enrolment in randomized clinical trials of heart failure with reduced ejection fraction to ensure evidence-based health care recommendations.
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2078.
    >> Share

  214. PIEPOLI MF, Hussain RI, Comin-Colet J, Dosantos R, et al
    OUTSTEP-HF: Randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Dec 13. doi: 10.1002/ejhf.2076.
    >> Share

  215. DOCHERTY KF, McMurray JJV
    SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure.
    Eur J Heart Fail. 2020 Dec 6. doi: 10.1002/ejhf.2075.
    >> Share

  216. ZELNIKER TA, Morrow DA, Mosenzon O, Goodrich EL, et al
    Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without SGLT2 inhibitor therapy in DECLARE-TIMI 58.
    Eur J Heart Fail. 2020 Dec 2. doi: 10.1002/ejhf.2073.
    >> Share


  217. Addendum to the article: 'Improving risk prediction in heart failure using machine learning' [Eur J Heart Fail 2020;22:139-147].
    Eur J Heart Fail. 2020;22:2399.
    >> Share

  218. WANG N, Cao J, Lal S
    COVID-19: getting to the heart of the matter.
    Eur J Heart Fail. 2020;22:2216-2218.
    >> Share

  219. TOMASONI D, Adamo M, Metra M
    December 2020 at a glance: focus on COVID-19, comorbidities and palliative care.
    Eur J Heart Fail. 2020;22:2173-2174.
    >> Share

  220. LEBEK S, Tafelmeier M, Messmann R, Provaznik Z, et al
    Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
    Eur J Heart Fail. 2020;22:2248-2257.
    >> Share

  221. BHATT AS, Vaduganathan M
    Discovery and care innovation amidst a pandemic.
    Eur J Heart Fail. 2020;22:2202-2204.
    >> Share

  222. FARMAKIS D
    Is cardio-oncology a rapidly growing field of precision medicine?
    Eur J Heart Fail. 2020;22:2310-2313.
    >> Share

  223. KONSTAM MA
    Ventricular remodelling: an equal-opportunity prognosticator.
    Eur J Heart Fail. 2020;22:2269-2271.
    >> Share

    November 2020
  224. PACKER M, Butler J, Filippatos G, Zannad F, et al
    Design of a Prospective Patient-Level Pooled Analysis of Two Parallel Trials of Empagliflozin in Patients With Established Heart Failure.
    Eur J Heart Fail. 2020 Nov 30. doi: 10.1002/ejhf.2065.
    >> Share

  225. GREENBERG B, Janvanishstaporn S, Feng S
    Reply to Letter: Worsening Renal Function After Diuresis Among Heart Failure Patients with Preserved Ejection Fraction --- A Dilemma to Heart Failure Management.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2067.
    >> Share

  226. ANKER SD, Butler J, Filippatos G, Khan MS, et al
    Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2064.
    >> Share

  227. BOORSMA EM, Beusekamp JC, Ter Maaten JM, Figarska SM, et al
    Effects of Empagliflozin on Renal Sodium and Glucose Handling in Patients with Acute Heart Failure.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2066.
    >> Share

  228. ANKER MS, Sanz AP, Zamorano JL, Mehra MR, et al
    Advanced cancer is also a heart failure syndrome - an hypothesis.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2071.
    >> Share

  229. MADELAIRE C, Kristensen SL
    Patterns of unplanned readmissions after heart failure hospitalization: novel longitudinal perspectives from Australia and New Zealand.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2068.
    >> Share

  230. D'AMARIO D, Borovac JA, Crea F
    Coronary microvascular dysfunction in heart failure with preserved ejection fraction: not the end but the end of the beginning.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2069.
    >> Share

  231. HALLIDAY BP, Owen R, Gregson J, Vassiliou V, et al
    Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy - insights from TRED-HF.
    Eur J Heart Fail. 2020 Nov 22. doi: 10.1002/ejhf.2063.
    >> Share

  232. CANEPA M, Kapelios CJ, Lund LH
    Acknowledging the complex puzzle that links heart failure hospitalizations and outcomes.
    Eur J Heart Fail. 2020 Nov 22. doi: 10.1002/ejhf.2061.
    >> Share

  233. DONAL E, Galli E, Paven E, Sade LE, et al
    Haemodynamic evaluation: a key tool for heart failure management.
    Eur J Heart Fail. 2020 Nov 20. doi: 10.1002/ejhf.2055.
    >> Share

  234. BIEGUS J, Zymlinski R, Testani J, Marciniak D, et al
    Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high risk acute heart failure patients.
    Eur J Heart Fail. 2020 Nov 14. doi: 10.1002/ejhf.2053.
    >> Share

  235. TOMASONI D, Inciardi RM, Lombardi CM, Tedino C, et al
    Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2052.
    >> Share

  236. VERNOOY K, Brunner-La Rocca HP
    The importance of the electrocardiographic follow-up in heart failure.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2054.
    >> Share

  237. DUSI V, Vitolo V, Frigerio L, Totaro R, et al
    The First-in-Man Case of Non-invasive Proton Radiotherapy to Treat Refractory Ventricular Tachycardia in Advanced Heart Failure.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2056.
    >> Share

  238. STARWALT JL, Ho AF, Wang H
    Worsening Renal Function After Diuresis Among Heart Failure Patients with Preserved Ejection Fraction --- A Dilemma to Heart Failure Management.
    Eur J Heart Fail. 2020 Nov 8. doi: 10.1002/ejhf.2050.
    >> Share

  239. KRESOJA KP, Rommel KP, Thiele H, Lurz P, et al
    Response to the letter regarding the article: Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2020 Nov 4. doi: 10.1002/ejhf.2048.
    >> Share

  240. KONIG S, Hohenstein S, Meier-Hellmann A, Kuhlen R, et al
    In-hospital Care in Acute Heart Failure during the COVID-19 Pandemic: Insights from the German-wide Helios Hospital Network.
    Eur J Heart Fail. 2020 Nov 2. doi: 10.1002/ejhf.2044.
    >> Share

  241. FABRIS E, Sinagra G, Valgimigli M
    Antithrombotic therapy in heart failure and sinus rhythm: the ongoing search for a better match of patients to therapy.
    Eur J Heart Fail. 2020 Nov 1. doi: 10.1002/ejhf.2045.
    >> Share

  242. VOLTERRANI M, Perrone V, Sangiorgi D, Giacomini E, et al
    Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study.
    Eur J Heart Fail. 2020;22:2049-2055.
    >> Share


  243. Corrigendum to 'Departments involved during the first episode of acute heart failure and analysis of emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort' [Eur J Heart Fail 2019;21:1231-1244].
    Eur J Heart Fail. 2020;22:2172.
    >> Share

  244. JANKOWSKA EA, Tkaczyszyn M, Ponikowski P
    Myocardial iron content in non-ischaemic cardiomyopathy: how much is known?
    Eur J Heart Fail. 2020;22:2047-2048.
    >> Share

  245. RICHARDS AM
    Beating the bushes for biomarkers.
    Eur J Heart Fail. 2020;22:2075-2077.
    >> Share

  246. OKWUOSA TM, Keramida K, Filippatos G, Yancy CW, et al
    Cancer therapy and the heart; the necessity to calibrate risk.
    Eur J Heart Fail. 2020;22:1961-1965.
    >> Share

  247. SEFEROVIC PM, Polovina M
    In search of a 'safety zone' for glycaemic control: association between glycosylated haemoglobin levels and outcomes in patients with type 2 diabetes and cardiovascular disease.
    Eur J Heart Fail. 2020;22:2035-2037.
    >> Share

  248. KEHLER DS, Arora RC
    Frailty and the failing heart do not travel alone.
    Eur J Heart Fail. 2020;22:2120-2122.
    >> Share

  249. COWIE MR
    DAPA-HF: does dapagliflozin provide 'bang for your buck' as a treatment for heart failure with reduced ejection fraction?
    Eur J Heart Fail. 2020;22:2157-2159.
    >> Share

    October 2020
  250. KOUDSTAAL S, Den Ruijter HM, Peters SAE
    Sex Differences and Heart Failure - A Story of Two Tales.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2041.
    >> Share

  251. WAGNER J, Ambrosy AP
    Hospitalizations for Heart Failure and Mortality Risk During the Evolving Coronavirus Disease 2019 Pandemic - The Wave May Break but A Dangerous Undertow Persists.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2043.
    >> Share

  252. AHMED F
    Letter regarding the article Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2037.
    >> Share

  253. PELLICORI P, Platz E, Dauw J, Ter Maaten JM, et al
    Ultrasound imaging of congestion in heart failure - Examinations beyond the heart.
    Eur J Heart Fail. 2020 Oct 29. doi: 10.1002/ejhf.2032.
    >> Share

  254. WHITELAW S, Sullivan K, Eliya Y, Alruwayeh M, et al
    Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: A systematic review.
    Eur J Heart Fail. 2020 Oct 29. doi: 10.1002/ejhf.2034.
    >> Share

  255. KLOMPSTRA L, Kyriakou M, Lambrinou E, Piepoli MF, et al
    Measuring physical activity with activity monitors in patients with heart failure. From literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiol
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2035.
    >> Share

  256. SIERPINSKI R, Josiak K, Suchocki T, Wojtas-Polc K, et al
    High Soluble Transferrin Receptor in Patients With Heart Failure: a Measure of Iron Deficiency And a Strong Predictor of Mortality.
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2036.
    >> Share

  257. BEKFANI T, Fudim M, Cleland JGF, Jorbenadze A, et al
    A Current and Future Outlook on Upcoming Technologies in the Remote Monitoring of Patients with Heart Failure.
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2033.
    >> Share

  258. CULIC V, Velat I
    Spironolactone discontinuation in patients with heart failure: complex interactions with loop diuretics.
    Eur J Heart Fail. 2020 Oct 23. doi: 10.1002/ejhf.2031.
    >> Share

  259. LABROSCIANO C, Horton D, Air T, Tavella R, et al
    Frequency, Trends and Institutional Variation in 30-Day All-Cause Mortality and Unplanned Readmissions Following Hospitalisation for Heart Failure in Australia and New Zealand.
    Eur J Heart Fail. 2020 Oct 23. doi: 10.1002/ejhf.2030.
    >> Share

  260. DE BOER RA, Hulot JS, Gabriele Tocchetti C, Aboumsallem JP, et al
    Common Mechanistic Pathways in Cancer and Heart Failure.
    Eur J Heart Fail. 2020 Oct 22. doi: 10.1002/ejhf.2029.
    >> Share

  261. SEFEROVIC PM, Fragasso G, Petrie M, Mullens W, et al
    Heart Failure Association of the European Society of Cardiology Update on Sodium Glucose Co-transporter-2 Inhibitors in Heart Failure (an update on the Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The position
    Eur J Heart Fail. 2020 Oct 17. doi: 10.1002/ejhf.2026.
    >> Share

  262. KOEHLER J, Stengel A, Hofmann T, Wegscheider K, et al
    Telemonitoring in patients with chronic heart failure and moderate depressed symptoms - results of the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study.
    Eur J Heart Fail. 2020 Oct 15. doi: 10.1002/ejhf.2025.
    >> Share

  263. KASSNER A, Oezpeker C, Gummert J, Zittermann A, et al
    Mechanical circulatory support does not reduce advanced myocardial fibrosis in patients with terminal heart failure.
    Eur J Heart Fail. 2020 Oct 10. doi: 10.1002/ejhf.2021.
    >> Share

  264. SAED ALHAKAK A, Sengelov M, Jorgensen PG, Bruun NE, et al
    Left Ventricular Systolic Ejection Time is an Independent Predictor of All-Cause Mortality in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2020 Oct 9. doi: 10.1002/ejhf.2022.
    >> Share

  265. ABRAHAM WT, Psotka MA, Fiuzat M, Filippatos G, et al
    Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium (HF-ARC).
    Eur J Heart Fail. 2020 Oct 5. doi: 10.1002/ejhf.2018.
    >> Share

  266. PUDIL R, Mueller C, Celutkiene J, Henriksen PA, et al
    The role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and Cardio-Oncology Council of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Oct 2. doi: 10.1002/ejhf.2017.
    >> Share

  267. COATS AJS
    Pulmonary artery pressure monitoring, a reality for Europe?
    Eur J Heart Fail. 2020;22:1905-1906.
    >> Share

  268. GUSTAFSSON F, Lund LH, Metra M
    If it ain't broken, don't fix it (but if it is, make sure you know): aortic valve interventions during left ventricular assist device implantation.
    Eur J Heart Fail. 2020;22:1888-1890.
    >> Share

  269. PARIKH PB, Tsigkas G, Kalogeropoulos AP
    Transcatheter aortic valve replacement after heart failure hospitalization: too little, too late?
    Eur J Heart Fail. 2020;22:1875-1877.
    >> Share

  270. ADAMO M, Metra M, Alfieri O
    Percutaneous valve repair of functional mitral regurgitation: aiming at optimal and durable results.
    Eur J Heart Fail. 2020;22:1849-1851.
    >> Share

  271. GRIFFIN JM, Maurer MS
    Cardiac amyloidosis in severe aortic stenosis: we can find it but what should we do?
    Eur J Heart Fail. 2020;22:1863-1865.
    >> Share

  272. SCHNEIDER M, Mascherbauer J
    Improvement in nutritional status - a determinant of successful transcatheter tricuspid valve repair?
    Eur J Heart Fail. 2020;22:1837-1839.
    >> Share

    September 2020
  273. TEERLINK JR, Diaz R, Felker GM, McMurray JJV, et al
    Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction, GALACTIC-HF: Baseline Characteristics and Comparison with Contemporary Clinical Trials.
    Eur J Heart Fail. 2020 Sep 27. doi: 10.1002/ejhf.2015.
    >> Share

  274. JAARSMA T, Celutkiene J, Lopatin Y, Vugrak L, et al
    Learning together: insights from the first Heart Failure Association Patient Forum.
    Eur J Heart Fail. 2020 Sep 23. doi: 10.1002/ejhf.2013.
    >> Share

  275. COATS AJ
    Figures of the Heart Failure Association: Prof Lars H. Lund, Chair of the HFA Committee on Registries, Surveys and Epidemiology and HFA Board Member (from 2016).
    Eur J Heart Fail. 2020 Sep 23. doi: 10.1002/ejhf.2014.
    >> Share

  276. FENG S, Janwanishstaporn S, Teerlink J, Metra M, et al
    Association of Left Ventricular Ejection Fraction with Worsening Renal Function in Patients with Acute Heart Failure: Insights from the RELAX-AHF-2 Study.
    Eur J Heart Fail. 2020 Sep 22. doi: 10.1002/ejhf.2012.
    >> Share

  277. FERREIRA JP, Lam CSP, Anker SD, Mehra MR, et al
    Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial.
    Eur J Heart Fail. 2020 Sep 21. doi: 10.1002/ejhf.2003.
    >> Share

  278. AHMAD A, Corban MT, Toya T, Verbrugge FH, et al
    Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2020 Sep 19. doi: 10.1002/ejhf.2010.
    >> Share

  279. MCMURRAY JJ
    EMPEROR-Reduced: Confirming sodium-glucose cotransporter 2 (SGLT2) inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Sep 18. doi: 10.1002/ejhf.2006.
    >> Share

  280. IBRAHIM NE, Pina IL, Camacho A, Bapat D, et al
    Sex-Based Differences in Biomarkers, Health Status, and Reverse Cardiac Remodeling in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/Valsartan.
    Eur J Heart Fail. 2020 Sep 18. doi: 10.1002/ejhf.2005.
    >> Share

  281. MONDRITZKI T, Mai TA, Vogel J, Pook E, et al
    Cardiac output improvement by pecavaptan: A novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.
    Eur J Heart Fail. 2020 Sep 18. doi: 10.1002/ejhf.2001.
    >> Share

  282. JAARSMA T, Hill L, Bayes-Genis A, Brunner La Rocca HP, et al
    Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Sep 18. doi: 10.1002/ejhf.2008.
    >> Share

  283. TAYLOR CJ, Ordonez-Mena JM, Jones NR, Roalfe AK, et al
    National Trends in Heart Failure Mortality in Men and Women, United Kingdom, 2000-2017.
    Eur J Heart Fail. 2020 Sep 6. doi: 10.1002/ejhf.1996.
    >> Share

  284. HILL L, Geller TP, Baruah R, Beattie JM, et al
    Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper.
    Eur J Heart Fail. 2020 Sep 6. doi: 10.1002/ejhf.1994.
    >> Share

  285. GRAZETTE LP, Goldberger JJ
    Addressing the sudden cardiac death conundrum in heart failure with preserved ejection fraction: do we need a microscope or a telescope?
    Eur J Heart Fail. 2020 Sep 6. doi: 10.1002/ejhf.1995.
    >> Share

  286. HASENFUSS G
    Is myosin activation a new treatment for heart failure?
    Eur J Heart Fail. 2020 Sep 2. doi: 10.1002/ejhf.1983.
    >> Share

  287. TOMASONI D, Adamo M, Metra M
    September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy.
    Eur J Heart Fail. 2020;22:1493-1494.
    >> Share

  288. KALOGEROPOULOS AP, Simitsis P, Skopicki HA
    Secrets of spironolactone: continuing insights from TOPCAT Americas.
    Eur J Heart Fail. 2020;22:1625-1627.
    >> Share

  289. RITCHIE R, Galougahi KK, Figtree GA
    Targeting longevity genes in the battle against diabetic heart disease - is there a gene delivery fountain of youth?
    Eur J Heart Fail. 2020;22:1582-1585.
    >> Share

  290. BISTOLA V, Polyzogopoulou E, Parissis J
    A novel strategy for the management of lung congestion: targeting TRPV4 channel, the 'gate keeper' of pulmonary capillary permeability.
    Eur J Heart Fail. 2020;22:1646-1648.
    >> Share

  291. ZIAEIAN B, Butler J, Fonarow GC
    With great power comes great... reliability.
    Eur J Heart Fail. 2020;22:1708-1710.
    >> Share

    August 2020
  292. SRIVASTAVA A, Heywood JT
    Replacing Art with Numbers: Decongesting Congestive Heart Failure.
    Eur J Heart Fail. 2020 Aug 27. doi: 10.1002/ejhf.1980.
    >> Share

  293. MCNAUGHTON CD, Collins SP, Testani JM
    Accelerated decline in renal function after hospitalization for acute heart failure: An opportunity to intervene, or a sign of the inevitable?
    Eur J Heart Fail. 2020 Aug 25. doi: 10.1002/ejhf.1992.
    >> Share

  294. SELVARAJ S, Claggett BL, Pfeffer MA, Desai AS, et al
    Serum Uric Acid, Influence of Sacubitril/Valsartan, and Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction: PARAGON-HF.
    Eur J Heart Fail. 2020 Aug 25. doi: 10.1002/ejhf.1984.
    >> Share

  295. REY JR, Caro-Codon J, Rosillo SO, Iniesta AM, et al
    Heart Failure In Covid-19 Patients: Prevalence, Incidence And Prognostic Implications.
    Eur J Heart Fail. 2020 Aug 24. doi: 10.1002/ejhf.1990.
    >> Share

  296. VERBRUGGE FH, Damman K
    Spironolactone: Diuretic or Disease-modifying Drug in Heart Failure with Preserved Ejection Fraction?
    Eur J Heart Fail. 2020 Aug 19. doi: 10.1002/ejhf.1979.
    >> Share

  297. CANNATA A, Bromage DI, Rind IA, Gregorio C, et al
    Temporal trends in decompensated heart failure and outcomes during COVID-19: A multisite report from heart failure referral centres in London.
    Eur J Heart Fail. 2020 Aug 18. doi: 10.1002/ejhf.1986.
    >> Share

  298. PIEK A, Suthahar N, Voors AA, de Boer RA, et al
    A combined bioinformatics, experimental and clinical approach to identify novel cardiac specific heart failure biomarkers: Is Dickkopf-3 (DKK3) a possible candidate?
    Eur J Heart Fail. 2020 Aug 18. doi: 10.1002/ejhf.1988.
    >> Share

  299. MCEWAN P, Darlington O, McMurray JJV, Jhund PS, et al
    Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
    Eur J Heart Fail. 2020 Aug 4. doi: 10.1002/ejhf.1978.
    >> Share

  300. AIMO A, Georgiopoulos G, Senni M, Emdin M, et al
    Searching for diagnostic biomarkers of heart failure with preserved ejection fraction: methodological issues.
    Eur J Heart Fail. 2020 Aug 4. doi: 10.1002/ejhf.1977.
    >> Share

  301. VADUGANATHAN M, McMurray JJV, Solomon SD
    Angiotensin Receptor-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction: Lessons from PARAGON-HF.
    Eur J Heart Fail. 2020 Aug 2. doi: 10.1002/ejhf.1976.
    >> Share

  302. KRESOJA KP, Lauten A, Orban M, Rommel KP, et al
    Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2020 Aug 2. doi: 10.1002/ejhf.1975.
    >> Share

  303. HOWLETT JG
    The time has finally come to prioritize drug initiation before dose titration for patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2020;22:1483-1485.
    >> Share

  304. MONTGOMERY RA, Tang WHW
    A means to an end: the promise of tracking natriuresis with diuretic therapy.
    Eur J Heart Fail. 2020;22:1448-1450.
    >> Share

    July 2020
  305. KRISTENSEN SL, Castagno D, Shen L, Jhund P, et al
    Prevalence and incidence of intraventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF and ATMOSPHERE.
    Eur J Heart Fail. 2020 Jul 28. doi: 10.1002/ejhf.1972.
    >> Share

  306. VADUGANATHAN M, Pareek M, Kristensen AMD, Biering-Sorensen T, et al
    Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy.
    Eur J Heart Fail. 2020 Jul 21. doi: 10.1002/ejhf.1971.
    >> Share

  307. VAN VELDHUISEN DJ, van Woerden G, Gorter TM, van Empel VPM, et al
    Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients with Heart Failure and Preserved Ejection Fraction: The VIP-HF study.
    Eur J Heart Fail. 2020 Jul 19. doi: 10.1002/ejhf.1970.
    >> Share

  308. MORTARA A, Margonato D
    Proactive management of heart failure by digital health: is monitoring of invasive pulmonary artery pressure the Holy Grail?
    Eur J Heart Fail. 2020 Jul 15. doi: 10.1002/ejhf.1966.
    >> Share

  309. ISRAR MZ, Salzano A, Yazaki Y, Voors AA, et al
    Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT-CHF.
    Eur J Heart Fail. 2020 Jul 14. doi: 10.1002/ejhf.1951.
    >> Share

  310. QUARTA G, Gori M, Iorio A, D'Elia E, et al
    Cardiovascular magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities.
    Eur J Heart Fail. 2020 Jul 12. doi: 10.1002/ejhf.1961.
    >> Share

  311. CELUTKIENE J, Pudil R, Lopez-Fernandez T, Grapsa J, et al
    The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a Position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of
    Eur J Heart Fail. 2020 Jul 4. doi: 10.1002/ejhf.1957.
    >> Share

  312. RAO VN, Fudim M, Mentz RJ, Michos ED, et al
    Regional Adiposity and Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2020 Jul 3. doi: 10.1002/ejhf.1956.
    >> Share

  313. BASIC C, Rosengren A, Alehagen U, Dahlstrom U, et al
    Young patients with heart failure - clinical characteristics and outcomes. Data from the Swedish Heart Failure, National Patient, Population and Cause of Death Registers.
    Eur J Heart Fail. 2020 Jul 2. doi: 10.1002/ejhf.1952.
    >> Share

  314. SEFEROVIC PM, Fragasso G, Petrie M, Mullens W, et al
    Sodium glucose co-transporter-2 inhibitors in heart failure: beyond glycaemic control. The Position Paper of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Jul 2. doi: 10.1002/ejhf.1954.
    >> Share

  315. AMBROSY AP, Fitzpatrick JK, Fudim M
    Hospitalizations for heart failure during the COVID-19 pandemic: making sense of the known knowns, known unknowns, and unknown unknowns.
    Eur J Heart Fail. 2020 Jul 2. doi: 10.1002/ejhf.1955.
    >> Share


  316. Corrigendum to 'Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry' [Eur J Heart Fail 2020;22:92-102].
    Eur J Heart Fail. 2020;22:1287.
    >> Share


  317. Corrigendum to 'Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry' [Eur J Heart Fail 2020;22:10
    Eur J Heart Fail. 2020;22:1287.
    >> Share


  318. Corrigendum to 'Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology' [Eur J Heart Fail 2020;22:181-195].
    Eur J Heart Fail. 2020;22:1287.
    >> Share

  319. EKSTROM K, Raisanen-Sokolowski A, Lehtonen J, Kupari M, et al
    Long-term outcome and its predictors in giant cell myocarditis. Letter regarding the article 'Long-term outcome and its predictors in giant cell myocarditis'.
    Eur J Heart Fail. 2020;22:1283-1284.
    >> Share

  320. SEFEROVIC PM, Asanin M, Polovina M
    Practice makes perfect: improved long-term survival in non-ischaemic dilated cardiomyopathy with contemporary treatment.
    Eur J Heart Fail. 2020;22:1122-1124.
    >> Share

  321. GORTER TM, van Veldhuisen DJ, Dickinson MG
    Right-sided cardiac disease: no longer the 'dark side of the heart'.
    Eur J Heart Fail. 2020;22:1226-1229.
    >> Share

  322. INCIARDI RM, Rossi A
    Mitral regurgitation, edge-to-edge valve repair and the left atrium: one step beyond the left ventricle?
    Eur J Heart Fail. 2020;22:1211-1213.
    >> Share

  323. SEFEROVIC PM, Polovina MM
    A new perspective of an old tool: an everlasting benefit of the electrocardiogram in dilated cardiomyopathy.
    Eur J Heart Fail. 2020;22:1108-1110.
    >> Share

  324. MICHEL L, Rassaf T, Totzeck M
    Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis? Reply.
    Eur J Heart Fail. 2020;22:1285-1286.
    >> Share

  325. AIMO A, Fabiani I, Emdin M
    Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis?. Letter regarding the article 'Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis.'
    Eur J Heart Fail. 2020;22:1284-1285.
    >> Share

  326. TER MAATEN JM, Said F, Maass AH
    Factors predicting recovery of left ventricular dysfunction in non-ischaemic cardiomyopathy.
    Eur J Heart Fail. 2020;22:1171-1173.
    >> Share

  327. ZWEERINK A, Allaart CP, Burri H
    Shifting diastolic filling from right to left in non-obstructive hypertrophic cardiomyopathy: exploring new indications for biventricular pacing.
    Eur J Heart Fail. 2020;22:1273-1275.
    >> Share

    June 2020
  328. YAMANAKA S, Sakata Y, Nochioka K, Miura M, et al
    Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction.
    Eur J Heart Fail. 2020 Jun 27. doi: 10.1002/ejhf.1945.
    >> Share

  329. HENKENS MTHM, Remmelzwaal S, Robinson EL, van Ballegooijen AJ, et al
    Risk of bias in studies investigating novel diagnostic biomarkers for Heart Failure with Preserved Ejection Fraction. A systematic review.
    Eur J Heart Fail. 2020 Jun 27. doi: 10.1002/ejhf.1944.
    >> Share

  330. MULDER BA, van Veldhuisen DJ, Rienstra M
    What should the C ("Congestive heart failure") represent in the CHA2 DS2 -VASc score?
    Eur J Heart Fail. 2020 Jun 27. doi: 10.1002/ejhf.1946.
    >> Share

  331. ANGERMANN CE, Assmus B, Anker SD, Asselbergs FW, et al
    Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF).
    Eur J Heart Fail. 2020 Jun 27. doi: 10.1002/ejhf.1943.
    >> Share

  332. OUWERKERK W, Teng TK, Tromp J, Tay WT, et al
    Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
    Eur J Heart Fail. 2020 Jun 25. doi: 10.1002/ejhf.1869.
    >> Share

  333. BARTKO PE, Goliasch G
    Tricuspid regurgitation secondary to heart failure: more pieces to solve the puzzle.
    Eur J Heart Fail. 2020 Jun 22. doi: 10.1002/ejhf.1941.
    >> Share

  334. ANGELINI F, Bocchino PP, Frea S, De Ferrari GM, et al
    Does end-organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The two-faced Janus.
    Eur J Heart Fail. 2020 Jun 22. doi: 10.1002/ejhf.1940.
    >> Share

  335. DE FILIPPO O, D'Ascenzo F, De Ferrari GM
    Heart failure related hospitalisation and management during COVID-19 pandemic: are we ready to reflect? - REPLY.
    Eur J Heart Fail. 2020 Jun 21. doi: 10.1002/ejhf.1939.
    >> Share

  336. VOORS AA, Tamby JF, Cleland JG, Koren M, et al
    Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial.
    Eur J Heart Fail. 2020 Jun 19. doi: 10.1002/ejhf.1933.
    >> Share

  337. GOETZE JP, Balling L, Deis T, Struck J, et al
    Bioactive adrenomedullin in plasma is associated to biventricular filling pressures in patients with advanced heart failure.
    Eur J Heart Fail. 2020 Jun 18. doi: 10.1002/ejhf.1937.
    >> Share

  338. ZYMLINSKI R, Ponikowski P, Biegus J
    Looking at the heart failure through the prism of liver dysfunction.
    Eur J Heart Fail. 2020 Jun 13. doi: 10.1002/ejhf.1932.
    >> Share

  339. AMBROSY AP, Chioncel O
    Improving Physical Activity and Exercise Capacity in Heart Failure Taking the First Step is Always the Hardest.
    Eur J Heart Fail. 2020 Jun 13. doi: 10.1002/ejhf.1934.
    >> Share

  340. FARMAKIS D, Butler J, Filippatos G
    Sodium-glucose co-transporter-2 inhibitors: "A Tale of Two Sisters", diabetes and heart failure.
    Eur J Heart Fail. 2020 Jun 13. doi: 10.1002/ejhf.1935.
    >> Share

  341. LYRA V, Parissis J, Kallergi M, Rizos E, et al
    (18) F-FDG PET/CT brain glucose metabolism as a marker of different types of depression comorbidity in chronic heart failure patients with impaired systolic function.
    Eur J Heart Fail. 2020 Jun 12. doi: 10.1002/ejhf.1866.
    >> Share

  342. NAZIR T
    Heart failure related hospitalisation and management during COVID-19 pandemic: are we ready to reflect?
    Eur J Heart Fail. 2020 Jun 10. doi: 10.1002/ejhf.1931.
    >> Share

  343. FARMAKIS D, Mehra MR, Parissis J, Filippatos G, et al
    Heart failure in the course of a pandemic.
    Eur J Heart Fail. 2020 Jun 7. doi: 10.1002/ejhf.1929.
    >> Share

  344. TARTIERE JM, Solal AC, Roubille F, Girerd N, et al
    Response to the letter "All rise! Orthostatic Hypotension in Heart Failure".
    Eur J Heart Fail. 2020 Jun 5. doi: 10.1002/ejhf.1927.
    >> Share

  345. MATSUE Y, Kamiya K, Saito H, Saito K, et al
    Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: The FRAGILE-HF cohort study.
    Eur J Heart Fail. 2020 Jun 5. doi: 10.1002/ejhf.1926.
    >> Share

  346. GROENEWEGEN A, Rutten FH, Mosterd A, Hoes AW, et al
    Epidemiology of heart failure.
    Eur J Heart Fail. 2020 Jun 1. doi: 10.1002/ejhf.1858.
    >> Share

  347. BROMAGE DI, Cannata A, Rind IA, Gregorio C, et al
    The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic.
    Eur J Heart Fail. 2020 Jun 1. doi: 10.1002/ejhf.1925.
    >> Share


  348. Erratum to 'New-onset heart failure in the STOP-HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure' [Eur J Heart Fail 2020;22:378-380].
    Eur J Heart Fail. 2020;22:1056.
    >> Share

  349. DE BROUWER R, van Veldhuisen DJ, de Boer RA
    Surviving the first COVID-19 wave and learning lessons for the second.
    Eur J Heart Fail. 2020;22:975-977.
    >> Share

  350. XANTHOPOULOS A, Triposkiadis F, Starling RC
    Care for patients with ventricular assist devices and suspected COVID-19 infection.
    Eur J Heart Fail. 2020;22:937-940.
    >> Share

  351. VAN LINTHOUT S, Klingel K, Tschope C
    SARS-CoV-2-related myocarditis-like syndromes Shakespeare's question: what's in a name?
    Eur J Heart Fail. 2020;22:922-925.
    >> Share

  352. ADAMO M, Lombardi CM, Metra M
    June 2020 at a glance: focus on COVID-19, quality of life and comorbidities.
    Eur J Heart Fail. 2020;22:917-918.
    >> Share

  353. BEAN DM, Kraljevic Z, Searle T, Bendayan R, et al
    Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.
    Eur J Heart Fail. 2020;22:967-974.
    >> Share

  354. FARMAKIS D, Keramida K, Filippatos G
    Cardio-oncology services during the COVID-19 pandemic: practical considerations and challenges.
    Eur J Heart Fail. 2020;22:929-932.
    >> Share

  355. BEN GAL T, Ben Avraham B, Abu-Hazira M, Frigerio M, et al
    The consequences of the COVID-19 pandemic for self-care in patients supported with a left ventricular assist device.
    Eur J Heart Fail. 2020;22:933-936.
    >> Share

  356. KLEIN P, Anker SD, Wechsler A, Kelle S, et al
    Left ventricular volume reduction and reshape - 'Re-STICHING' the field. Reply.
    Eur J Heart Fail. 2020;22:1053-1054.
    >> Share

  357. FERREIRA JP
    Health-related quality of life scores: ending the minimum 5-point difference as the clinically meaningful threshold.
    Eur J Heart Fail. 2020;22:1006-1008.
    >> Share

  358. BONIOS MJ, Kogerakis N, Adamopoulos SN
    Left ventricular volume reduction and reshape - 'Re-STICHING' the field. Letter regarding the article 'Less invasive ventricular reconstruction for ischaemic heart failure'.
    Eur J Heart Fail. 2020;22:1053.
    >> Share

    May 2020
  359. MULLENS W, Sharif F, Dupont M, Rothman AMK, et al
    Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first-in-human study.
    Eur J Heart Fail. 2020 May 31. doi: 10.1002/ejhf.1870.
    >> Share

  360. KALOGEROPOULOS AP, Thankachen J, Butler J, Fang JC, et al
    Diuretic and Renal Effects of Spironolactone and Heart Failure Hospitalizations: A TOPCAT Americas Analysis.
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1917.
    >> Share

  361. CHIONCEL O, Parissis J, Mebazaa A, Thiele H, et al
    Epidemiology, Pathophysiology and Contemporary Management of Cardiogenic Shock - A position statement from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1922.
    >> Share

  362. COX ZL, Lai P, Lindenfeld J
    Deceases in Acute Heart Failure Hospitalizations during COVID-19.
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1921.
    >> Share

  363. PIEPOLI MF, Ponikowski PP, Volterrani M, Francis DP, et al
    Do Cheyne and Stokes have an important message for modern-day patients with heart failure? Yes they do.
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1923.
    >> Share

  364. SBOLLI M, Fiuzat M, Cani D, O'Connor CM, et al
    Depression and heart failure: the lonely comorbidity.
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1865.
    >> Share

  365. EDELMANN F, Jaarsma T, Comin-Colet J, Schorr J, et al
    Rationale and Study Design of OUTSTEP-HF: A Randomized Controlled Study to Assess the Effect of Sacubitril/Valsartan and Enalapril on Physical Activity measured by Accelerometry in Patients with Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1919.
    >> Share

  366. BAJAJ NS, Vaduganathan M
    Using antimatter to uncover what matters: metformin effects on myocardial efficiency in heart failure.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1856.
    >> Share

  367. LYON AR, Dent S, Stanway S, Earl H, et al
    Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Soci
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1920.
    >> Share

  368. ZHANG Y, Stewart Coats AJ, Zheng Z, Adamo M, et al
    Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1915.
    >> Share

  369. SALZANO A, D'Assante R, Stagnaro FM, Valente V, et al
    Heart failure management during COVID-19 outbreak in Italy. Telemedicine experience from a heart failure university tertiary referral centre.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1911.
    >> Share

  370. VELAGALETI RS, Larson MG, Enserro D, Song RJ, et al
    Clinical Course after a First Episode of Heart Failure: Insights from the Framingham Heart Study.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1918.
    >> Share

  371. FUDIM M, Soloveva A
    All rise! Orthostatic Hypotension in Heart Failure.
    Eur J Heart Fail. 2020 May 27. doi: 10.1002/ejhf.1904.
    >> Share

  372. FARMAKIS D, Thodi M, Elpidoforou M, Filippatos G, et al
    Assessing frailty in heart failure.
    Eur J Heart Fail. 2020 May 27. doi: 10.1002/ejhf.1905.
    >> Share

  373. REDDY YNV, Borlaug BA
    New Insights into the Role of Left Atrial Function During Exercise in Heart Failure.
    Eur J Heart Fail. 2020 May 27. doi: 10.1002/ejhf.1903.
    >> Share

  374. FERREIRA JP, Rossello X, Pocock SJ, Rossignol P, et al
    Spironolactone dose in Heart Failure with Preserved Ejection Fraction: findings from TOPCAT.
    Eur J Heart Fail. 2020 May 25. doi: 10.1002/ejhf.1909.
    >> Share

  375. SLIWA K, Bauersachs J, Coats AJ
    The European Society of Cardiology Heart Failure Association Study Group on Peripartum Cardiomyopathy - what has been achieved in 10 years.
    Eur J Heart Fail. 2020 May 25. doi: 10.1002/ejhf.1912.
    >> Share

  376. SANTIAGO-VACAS E, Lupon J, Gavidia-Bovadilla G, Gual-Capllonch F, et al
    Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15-year prospective longitudinal trajectories in survivors.
    Eur J Heart Fail. 2020 May 25. doi: 10.1002/ejhf.1862.
    >> Share

  377. ROSSIGNOL P, Williams B, Mayo MR, Warren S, et al
    Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.
    Eur J Heart Fail. 2020 May 25. doi: 10.1002/ejhf.1860.
    >> Share

  378. PACKER M, Lam CSP, Lund LH, Maurer MS, et al
    Characterization of the Inflammatory-Metabolic Phenotype of Heart Failure and a Preserved Ejection Fraction: a Hypothesis to Explain Influence of Sex on the Evolution and Potential Treatment of the Disease.
    Eur J Heart Fail. 2020 May 22. doi: 10.1002/ejhf.1902.
    >> Share

  379. GIANNONI A, Borrelli C, Mirizzi G, Richerson GB, et al
    Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial.
    Eur J Heart Fail. 2020 May 22. doi: 10.1002/ejhf.1854.
    >> Share

  380. CHEN S, Redfors B, Crowley A, Ben-Yehuda O, et al
    Impact of recent heart failure hospitalization on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the PARTNER 2 trial and registries.
    Eur J Heart Fail. 2020 May 22. doi: 10.1002/ejhf.1841.
    >> Share

  381. GALINIER M, Roubille F, Berdague P, Brierre G, et al
    Telemonitoring versus standard of care in heart failure: a randomised multicentre trial.
    Eur J Heart Fail. 2020 May 21. doi: 10.1002/ejhf.1906.
    >> Share

  382. GUAZZI M, Moroni A
    The Dilemma of Renin Angiotensin System Blockers in Coronavirus Disease (Covid-19): Insights on the Lung Fluid Handling and Gas Exchange in Heart Failure Patients.
    Eur J Heart Fail. 2020 May 21. doi: 10.1002/ejhf.1910.
    >> Share

  383. KAPELIOS CJ, Lund LH
    Do chronic heart failure patients receive optimal decongestive interventions in a real-life setting?: Reply.
    Eur J Heart Fail. 2020 May 20. doi: 10.1002/ejhf.1859.
    >> Share

  384. PACKER M, Metra M
    Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction.
    Eur J Heart Fail. 2020 May 20. doi: 10.1002/ejhf.1857.
    >> Share

  385. D'AMARIO D, Restivo A, Canonico F, Rodolico D, et al
    Experience of Remote Cardiac Care during Covid-19 Pandemic: the V-LAP device in advanced heart failure.
    Eur J Heart Fail. 2020 May 19. doi: 10.1002/ejhf.1900.
    >> Share

  386. TOMASONI D, Italia L, Adamo M, Inciardi RM, et al
    COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.
    Eur J Heart Fail. 2020 May 15. doi: 10.1002/ejhf.1871.
    >> Share

  387. SUZUKI K, Claggett B, Minamisawa M, Packer M, et al
    Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 May 14. doi: 10.1002/ejhf.1853.
    >> Share

  388. VON HAEHLING S, Arzt M, Doehner W, Edelmann F, et al
    Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials.
    Eur J Heart Fail. 2020 May 11. doi: 10.1002/ejhf.1838.
    >> Share

  389. COATS AJS
    Exergaming for heart failure: an idea so good it just ought to work.
    Eur J Heart Fail. 2020 May 11. doi: 10.1002/ejhf.1842.
    >> Share

  390. GLENISTER RT, McCullough PA
    Analysing risk in heart failure: a Kalium check.
    Eur J Heart Fail. 2020 May 10. doi: 10.1002/ejhf.1855.
    >> Share

  391. CLELAND JG, Clark RA, Pellicori P, Inglis SC, et al
    Caring for people with heart failure and many other medical problems through and beyond the COVID-19 pandemic; the advantages of universal-access to home telemonitoring.
    Eur J Heart Fail. 2020 May 9. doi: 10.1002/ejhf.1864.
    >> Share

  392. OUWERKERK W, Tromp J, Jin X, Jaufeerally F, et al
    Heart failure with preserved ejection fraction diagnostic scores in an Asian population.
    Eur J Heart Fail. 2020 May 6. doi: 10.1002/ejhf.1851.
    >> Share

  393. KHAN MS, Butler J, Greene SJ
    The real world of de novo heart failure: the next frontier for heart failure clinical trials?
    Eur J Heart Fail. 2020 May 6. doi: 10.1002/ejhf.1844.
    >> Share

  394. CHIONCEL O, Collins SP, Butler J
    Istaroxime in acute heart failure: the holy grail is at HORIZON?
    Eur J Heart Fail. 2020 May 6. doi: 10.1002/ejhf.1843.
    >> Share

  395. MESSIKA-ZEITOUN D, Verta P, Gregson J, Pocock SJ, et al
    Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis.
    Eur J Heart Fail. 2020 May 5. doi: 10.1002/ejhf.1830.
    >> Share

  396. ADAMO M, Lombardi CM, Metra M
    May 2020 at a glance: ischaemic heart failure and sex-related differences.
    Eur J Heart Fail. 2020;22:761-762.
    >> Share

  397. TAVAZZI G, Pellegrini C, Maurelli M, Belliato M, et al
    Myocardial localization of coronavirus in COVID-19 cardiogenic shock.
    Eur J Heart Fail. 2020;22:911-915.
    >> Share

  398. HAWKINS NM, Osmanska J, Petrie MC
    Implantable cardioverter-defibrillators and survival - the fine line between efficacy concerns and ageism.
    Eur J Heart Fail. 2020;22:868-870.
    >> Share

  399. BOLLI R, Kahlon A
    Time to end the war on cell therapy.
    Eur J Heart Fail. 2020;22:893-897.
    >> Share

  400. FURTADO RHM, Bergmark B
    Ejection fraction versus B-type natriuretic peptide for revascularization strategy in left main disease: two sides of the same coin or a wooden nickel?
    Eur J Heart Fail. 2020;22:880-883.
    >> Share

  401. CHATTERJEE NA, Levy WC
    Sudden cardiac death after myocardial infarction.
    Eur J Heart Fail. 2020;22:856-858.
    >> Share

    April 2020
  402. CAUTELA J, Tartiere JM, Cohen-Solal A, Bellemain-Appaix A, et al
    Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1835.
    >> Share

  403. DEWAN P, Jackson A, Jhund PS, Shen L, et al
    The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1832.
    >> Share

  404. ALMUFLEH A, Desai AS, Fay R, Ferreira JP, et al
    Correlation of laboratory haemoconcentration measures with filling pressures obtained via pulmonary arterial pressure sensors in ambulatory heart failure patients.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1848.
    >> Share

  405. AIMO A, Castiglione V, Lombardi CM
    Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1852.
    >> Share

  406. ELHARRAM M, Ferreira JP, Sharma A
    The intersecting role of glycaemia and cardiac function in the development of heart failure among patients with type 2 diabetes mellitus after an acute coronary syndrome.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1845.
    >> Share

  407. SUGIMOTO T, Barletta M, Bandera F, Generati G, et al
    Central role of left atrial dynamics in limiting exercise cardiac output increase and oxygen uptake in heart failure: insights by cardiopulmonary imaging.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1829.
    >> Share

  408. AIMO A, Barison A, Castiglione V, Emdin M, et al
    The unbearable underreporting of comorbidities in heart failure clinical trials.
    Eur J Heart Fail. 2020 Apr 29. doi: 10.1002/ejhf.1846.
    >> Share

  409. SIMONAVICIUS J, Brunner-La Rocca HP
    Do chronic heart failure patients receive optimal decongestive interventions in a real-life setting?
    Eur J Heart Fail. 2020 Apr 29. doi: 10.1002/ejhf.1839.
    >> Share

  410. HARJOLA VP, Parissis J, Bauersachs J, Brunner-La Rocca HP, et al
    Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Apr 29. doi: 10.1002/ejhf.1831.
    >> Share

  411. HENRI C, Mielniczuk L, O'Meara E
    Age and biomarkers in heart failure: challenging the current model to select patients for clinical trials.
    Eur J Heart Fail. 2020 Apr 16. doi: 10.1002/ejhf.1817.
    >> Share

  412. JAARSMA T, Hill L, Stromberg A
    What is what? From a palliative care approach to specialized palliative care in heart failure management.
    Eur J Heart Fail. 2020 Apr 16. doi: 10.1002/ejhf.1823.
    >> Share

  413. DAMMAN K, Ter Maaten JM, van der Meer P
    Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients? Reply.
    Eur J Heart Fail. 2020 Apr 16. doi: 10.1002/ejhf.1825.
    >> Share

  414. TROMBARA F, Apostolo A, Vignati C, Agostoni P, et al
    Why do left ventricular assist device recipients remain heart failure patients? Reply.
    Eur J Heart Fail. 2020 Apr 15. doi: 10.1002/ejhf.1824.
    >> Share

  415. PARMA Z, Jasilek A, Greenlaw N, Ferrari R, et al
    Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective CLARIFY registry.
    Eur J Heart Fail. 2020 Apr 15. doi: 10.1002/ejhf.1827.
    >> Share

  416. TRIPOSKIADIS F, Xanthopoulos A, Butler J
    From PARADIGM to PARAGON Further Evidence Supporting Continuous Heart Failure Spectrum.
    Eur J Heart Fail. 2020 Apr 15. doi: 10.1002/ejhf.1837.
    >> Share

  417. KHAN MS, Samman Tahhan A, Vaduganathan M, Greene SJ, et al
    Trends in prevalence of comorbidities in heart failure clinical trials.
    Eur J Heart Fail. 2020 Apr 15. doi: 10.1002/ejhf.1818.
    >> Share

  418. MALIK ME, Madelaire C, D'Souza M, Blanche P, et al
    Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease.
    Eur J Heart Fail. 2020 Apr 4. doi: 10.1002/ejhf.1819.
    >> Share

  419. SAMA IE, Woolley RJ, Nauta JF, Romaine SPR, et al
    A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1811.
    >> Share

  420. ROSSIGNOL P, Lainscak M, Crespo-Leiro MG, Laroche C, et al
    Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1793.
    >> Share

  421. VAN DER WAL HH, Beverborg NG, Ter Maaten JM, Vinke JSJ, et al
    Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1801.
    >> Share

  422. RUSSO D, Musumeci MB, Volpe M
    The neglected issue of cardiac amyloidosis in trials on heart failure with preserved ejection fraction in the elderly.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1766.
    >> Share

  423. STIENEN S, Ferreira JP, Pitt B, Cleland JG, et al
    Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1812.
    >> Share

  424. BUTLER J, Khan MS, Mori C, Filippatos GS, et al
    Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2020 Apr 2. doi: 10.1002/ejhf.1810.
    >> Share

  425. KAPELIOS CJ, Laroche C, Crespo-Leiro MG, Anker SD, et al
    Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2020 Apr 1. doi: 10.1002/ejhf.1796.
    >> Share

  426. DE DENUS S, Leclair G, Dube MP, St-Jean I, et al
    Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.
    Eur J Heart Fail. 2020 Apr 1. doi: 10.1002/ejhf.1802.
    >> Share

  427. GALLUZZO A, Bertaina M, Frea S
    Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients?
    Eur J Heart Fail. 2020 Apr 1. doi: 10.1002/ejhf.1814.
    >> Share

  428. METRA M, Lucioli P
    Corrigendum to 'Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015' [Eur J Heart Fail 2019;21:1329-1337].
    Eur J Heart Fail. 2020;22:759.
    >> Share

  429. DE LUCA L, Savonitto S
    Composite trends of cardiogenic shock complicating acute myocardial infarction.
    Eur J Heart Fail. 2020;22:673-675.
    >> Share

    March 2020
  430. POZZOLI M, Gonzalez-Costello J, Bayes-Genis A, Sinagra G, et al
    Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1789.
    >> Share

  431. LOARDI C, Zanobini M
    Why do left ventricular assist device recipients remain heart failure patients?
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1807.
    >> Share

  432. DAVISON BA, Takagi K, Senger S, Koch G, et al
    Mega-trials in heart failure: effects of dilution in examination of new therapies.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1780.
    >> Share

  433. BUTT JH, Fosbol EL, Gerds TA, Andersson C, et al
    Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1800.
    >> Share

  434. STEWART GM, Johnson BD, Sprecher DL, Reddy YNV, et al
    Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1809.
    >> Share

  435. BOUABDALLAOUI N, Rouleau J
    Evolving towards a more realistic approach to the importance of left ventricular ejection fraction and sex in heart failure and its therapy.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1805.
    >> Share

  436. SUTHAHAR N, Meems LMG, Ho JE, de Boer RA, et al
    Sex-related differences in contemporary biomarkers for heart failure: a review.
    Eur J Heart Fail. 2020 Mar 27. doi: 10.1002/ejhf.1771.
    >> Share

  437. SHIN SH, Claggett B, Pfeffer MA, Skali H, et al
    Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome.
    Eur J Heart Fail. 2020 Mar 25. doi: 10.1002/ejhf.1790.
    >> Share

  438. BHATT AS, Ambrosy AP, Dunning A, DeVore AD, et al
    The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF.
    Eur J Heart Fail. 2020 Mar 25. doi: 10.1002/ejhf.1795.
    >> Share

  439. KRAMER F, Voss S, Roessig L, Igl BW, et al
    Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Mar 25. doi: 10.1002/ejhf.1787.
    >> Share

  440. MORDI IR, Ouwerkerk W, Anker SD, Cleland JG, et al
    Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF.
    Eur J Heart Fail. 2020 Mar 25. doi: 10.1002/ejhf.1799.
    >> Share

  441. SEFEROVIC PM, Piepoli MF, Lopatin Y, Jankowska E, et al
    Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document.
    Eur J Heart Fail. 2020 Mar 18. doi: 10.1002/ejhf.1784.
    >> Share

  442. SAHLOLLBEY N, Lee CKS, Shirin A, Joseph P, et al
    The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials.
    Eur J Heart Fail. 2020 Mar 16. doi: 10.1002/ejhf.1783.
    >> Share

  443. MADAN S, Mehra MR
    Gut dysbiosis and heart failure: navigating the universe within.
    Eur J Heart Fail. 2020 Mar 13. doi: 10.1002/ejhf.1792.
    >> Share

  444. JAARSMA T, Klompstra L, Ben Gal T, Ben Avraham B, et al
    Effects of exergaming on exercise capacity in patients with heart failure: results of an international multicentre randomized controlled trial.
    Eur J Heart Fail. 2020 Mar 13. doi: 10.1002/ejhf.1754.
    >> Share

  445. ROSSIGNOL P, Zannad F
    Hypo- and hyperkalaemia in heart failure. Navigating between Scylla and Charybdis.
    Eur J Heart Fail. 2020 Mar 13. doi: 10.1002/ejhf.1791.
    >> Share

  446. HIRSCH VG, Tongers J, Bode J, Berliner D, et al
    Cardiac iron concentration in relation to systemic iron status and disease severity in non-ischaemic heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Mar 10. doi: 10.1002/ejhf.1781.
    >> Share

  447. KHAN MS, Butler J, Greene SJ
    Patient-reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life.
    Eur J Heart Fail. 2020 Mar 10. doi: 10.1002/ejhf.1762.
    >> Share

  448. REDDY YNV, Rikhi A, Obokata M, Shah SJ, et al
    Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity.
    Eur J Heart Fail. 2020 Mar 9. doi: 10.1002/ejhf.1788.
    >> Share

  449. JANWANISHSTAPORN S, Feng S, Teerlink J, Metra M, et al
    Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial.
    Eur J Heart Fail. 2020 Mar 5. doi: 10.1002/ejhf.1772.
    >> Share

  450. PIESKE B, Tschope C, de Boer RA, Fraser AG, et al
    How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur J Heart Fail. 2020 Mar 5. doi: 10.1002/ejhf.1741.
    >> Share

  451. COATS AJS
    Figures of the Heart Failure Association (HFA): Dr. Rudolf de Boer, HFA Board Member (2014-2020), Chair of the Basic Science Section (2016-2018), coordinator of the Study Group on Heart Failure with Preserved Ejection Fraction, and member of the HFA s
    Eur J Heart Fail. 2020 Mar 4. doi: 10.1002/ejhf.1779.
    >> Share

  452. DE BUYZERE ML, Delanghe JR
    Fibroblast growth factor 23 and the quest for the Holy Grail in heart failure: will the Crusaders be forced to surrender?
    Eur J Heart Fail. 2020 Mar 4. doi: 10.1002/ejhf.1786.
    >> Share

  453. SEFEROVIC PM, Jankowska E, Coats AJS, Maggioni AP, et al
    The Heart Failure Association Atlas: rationale, objectives, and methods.
    Eur J Heart Fail. 2020 Mar 3. doi: 10.1002/ejhf.1768.
    >> Share

  454. DEWAN P, Jackson A, Lam CSP, Pfeffer MA, et al
    Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure.
    Eur J Heart Fail. 2020 Mar 2. doi: 10.1002/ejhf.1776.
    >> Share

  455. COATS AJS
    Vericiguat for heart failure and the VICTORIA trial - the dog that didn't bark?
    Eur J Heart Fail. 2020 Mar 1. doi: 10.1002/ejhf.1778.
    >> Share

  456. ADAMO M, Lombardi CM, Metra M
    March 2020 at a glance: heart failure with preserved ejection fraction, left atrial myopathy, atrial fibrillation and cardiac amyloidosis.
    Eur J Heart Fail. 2020;22:389-390.
    >> Share

  457. STEWART COATS AJ
    Validating the HFA-PEFF score - or how to define a disease?
    Eur J Heart Fail. 2020;22:428-431.
    >> Share

  458. WESTIN O, Fosbol E, Gustafsson F
    Refining the role of carpal tunnel syndrome in cardiac amyloidosis.
    Eur J Heart Fail. 2020;22:516-518.
    >> Share

  459. SHEN L, Jhund P, McMurray J
    Dyslipidaemia, a factor worthy of adjustment: reply.
    Eur J Heart Fail. 2020;22:564-565.
    >> Share

  460. SKELIN M, Lucijanic M, Lucijanic J
    Dyslipidaemia, a factor worthy of adjustment.
    Eur J Heart Fail. 2020;22:564.
    >> Share

    February 2020
  461. STOLFO D, Savarese G
    Sex-related differences in therapeutic response to mineralocorticoid receptor antagonists in heart failure: summarizing trial evidence.
    Eur J Heart Fail. 2020 Feb 26. doi: 10.1002/ejhf.1761.
    >> Share

  462. KARASON K, Lund LH, Dalen M, Bjorklund E, et al
    Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) tr
    Eur J Heart Fail. 2020 Feb 26. doi: 10.1002/ejhf.1773.
    >> Share

  463. THOMPSON DR, Clark AM
    Heart failure disease management interventions: time for a reappraisal.
    Eur J Heart Fail. 2020 Feb 24. doi: 10.1002/ejhf.1777.
    >> Share

  464. BEHNES M, Schupp T, Mashayekhi K, Akin I, et al
    'Off-pump' left ventricular reconstruction - A causal and less invasive surgical option for patients with advanced systolic heart failure?
    Eur J Heart Fail. 2020 Feb 22. doi: 10.1002/ejhf.1737.
    >> Share

  465. DAMMAN K, Ter Maaten JM, Coster JE, Krikken JA, et al
    Clinical importance of urinary sodium excretion in acute heart failure.
    Eur J Heart Fail. 2020 Feb 22. doi: 10.1002/ejhf.1753.
    >> Share

  466. KRISTENSEN SL, McMurray JJV
    Diagnosing heart failure with preserved ejection fraction - what's the score?
    Eur J Heart Fail. 2020 Feb 22. doi: 10.1002/ejhf.1764.
    >> Share

  467. ARMSTRONG PW, Pieske B, O'Connor CM
    Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Reply.
    Eur J Heart Fail. 2020 Feb 21. doi: 10.1002/ejhf.1765.
    >> Share

  468. COOPER LB, Benson L, Mentz RJ, Savarese G, et al
    Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2020 Feb 20. doi: 10.1002/ejhf.1757.
    >> Share

  469. GROENEWEGEN A, Rutten FH
    Sodium-glucose co-transporter 2 inhibitors and acute heart failure.
    Eur J Heart Fail. 2020 Feb 18. doi: 10.1002/ejhf.1759.
    >> Share

  470. REDDY YNV, Borlaug BA
    Hypertension and heart failure: insights from exercise stress testing.
    Eur J Heart Fail. 2020 Feb 18. doi: 10.1002/ejhf.1760.
    >> Share

  471. NJOROGE JN, Teerlink JR
    Systolic time intervals in patients with heart failure: time to teach new dogs old tricks.
    Eur J Heart Fail. 2020 Feb 13. doi: 10.1002/ejhf.1725.
    >> Share

  472. STOHR R, Brandenburg VM, Heine GH, Maeder MT, et al
    Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial.
    Eur J Heart Fail. 2020 Feb 5. doi: 10.1002/ejhf.1749.
    >> Share

  473. JONES NR, Roalfe AK, Adoki I, Taylor CJ, et al
    Survival rates in elderly patients with heart failure: reply.
    Eur J Heart Fail. 2020 Feb 5. doi: 10.1002/ejhf.1751.
    >> Share

  474. ADAMO M, Lombardi CM, Metra M
    February 2020 at a glance: acute heart failure and cardio-oncology.
    Eur J Heart Fail. 2020;22:171-172.
    >> Share

  475. GRODIN JL, Rao A, Zaha VG
    Myocardial dysfunction in breast cancer survivors: 'you can observe a lot by just watching'.
    Eur J Heart Fail. 2020;22:347-349.
    >> Share

  476. MAGLIOCCA A, Omland T, Latini R
    Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more.
    Eur J Heart Fail. 2020;22:300-302.
    >> Share

  477. RAJU B, McCullough PA
    Circulating plasma dipeptidyl dipeptidase 3 and the prognosis of cardiogenic shock.
    Eur J Heart Fail. 2020;22:287-289.
    >> Share

    January 2020
  478. BORIANI G, Imberti JF, Vitolo M
    Atrial fibrillation and remote monitoring through cardiac implantable electronic devices in heart failure patients.
    Eur J Heart Fail. 2020 Jan 23. doi: 10.1002/ejhf.1745.
    >> Share

  479. CARUBELLI V, Zhang Y, Metra M, Lombardi C, et al
    Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial.
    Eur J Heart Fail. 2020 Jan 23. doi: 10.1002/ejhf.1743.
    >> Share

  480. KALUZA J, Levitan EB, Michaelsson K, Wolk A, et al
    Anti-inflammatory diet and risk of heart failure: two prospective cohort studies.
    Eur J Heart Fail. 2020 Jan 23. doi: 10.1002/ejhf.1746.
    >> Share

  481. PUGLIESE NR, Mazzola M, Fabiani I, Gargani L, et al
    Haemodynamic and metabolic phenotyping of hypertensive patients with and without heart failure by combining cardiopulmonary and echocardiographic stress test.
    Eur J Heart Fail. 2020 Jan 16. doi: 10.1002/ejhf.1739.
    >> Share

  482. MAURER MS, Packer M
    Impaired systemic venous capacitance: the neglected mechanism in patients with heart failure and a preserved ejection fraction?
    Eur J Heart Fail. 2020 Jan 16. doi: 10.1002/ejhf.1702.
    >> Share

  483. PELLICORI P, Ferreira JP, Mariottoni B, Brunner-La Rocca HP, et al
    Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing
    Eur J Heart Fail. 2020 Jan 16. doi: 10.1002/ejhf.1716.
    >> Share

  484. BUTLER J, Handelsman Y, Bakris G, Verma S, et al
    Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
    Eur J Heart Fail. 2020 Jan 11. doi: 10.1002/ejhf.1708.
    >> Share

  485. JHUND PS
    The recurring problem of heart failure hospitalisations.
    Eur J Heart Fail. 2020 Jan 11. doi: 10.1002/ejhf.1721.
    >> Share

  486. REDDY YNV, Borlaug BA
    Left atrial myopathy in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1688.
    >> Share

  487. KHAN MS, Memon MM, Murad MH, Vaduganathan M, et al
    Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1643.
    >> Share

  488. ROSSIGNOL P, Duarte K, Girerd N, Karoui M, et al
    Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1724.
    >> Share

  489. RIVAS-LASARTE M, Alvarez-Garcia J, Mirabet S, Sionis A, et al
    Is lung ultrasound monitoring really useful for impacting rehospitalization and mortality in worsening heart failure? Reply.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1719.
    >> Share

  490. KLOOSTERMAN M, Santema BT, Roselli C, Nelson CP, et al
    Genetic risk and atrial fibrillation in patients with heart failure.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1735.
    >> Share

  491. AIMO A, Januzzi JL Jr, Vergaro G, Richards AM, et al
    Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1701.
    >> Share

  492. BAUERSACHS J, Veltmann C
    Heart rate control in heart failure with reduced ejection fraction: the bright and the dark side of the moon.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1733.
    >> Share

  493. DAMMAN K, Beusekamp JC, Boorsma EM, Swart HP, et al
    Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1713.
    >> Share

  494. PETUTSCHNIGG J, Ferreira JP, Holzendorf V, Trippel TD, et al
    Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1723.
    >> Share

  495. VAN LINTHOUT S, Rimoldi O, Tschope C, Camici PG, et al
    Coronary microvascular dysfunction in heart failure with preserved ejection fraction - adding new pieces to the jigsaw puzzle.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1720.
    >> Share

  496. ZAKERI R, Morgan JM, Phillips P, Kitt S, et al
    Impact of remote monitoring on clinical outcomes for patients with heart failure and atrial fibrillation: results from the REM-HF trial.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1709.
    >> Share

  497. TAMARGO M, Obokata M, Reddy YNV, Pislaru SV, et al
    Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1699.
    >> Share

  498. MULLENS W, Damman K, Testani JM, Martens P, et al
    Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1697.
    >> Share

  499. MCCLELLAND S, Zhou S, O'Connell E, Gallagher J, et al
    New-onset heart failure in the STOP-HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1661.
    >> Share


  500. Corrigendum to 'Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU' [Eur J Heart Fail 2019;21:322-333].
    Eur J Heart Fail. 2020;22:170.
    >> Share

  501. MEWTON N, Cucherat M
    To clip, or not to clip heart failure patients, that is the question.
    Eur J Heart Fail. 2020;22:16-19.
    >> Share

  502. SCHLENDORF K, Stone GW, Abraham WT, Mack MJ, et al
    Who and when to clip: that is the question.
    Eur J Heart Fail. 2020;22:20-22.
    >> Share

  503. HARRISON SL, Lane DA, Lip GYH
    Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes.
    Eur J Heart Fail. 2020;22:136-138.
    >> Share

  504. HO G, Wettersten N, Greenberg B
    Implantable cardioverter-defibrillator therapy in patients with left ventricular assist devices: a shocking tale of survival.
    Eur J Heart Fail. 2020;22:29-31.
    >> Share

  505. HELGESTAD OKL, Ravn HB, Josiassen J, Udesen NLJ, et al
    Mechanical respiratory support in cardiogenic shock: reply.
    Eur J Heart Fail. 2020;22:168-169.
    >> Share

  506. MILLER PE, Gimenez MR, Thiele H
    Mechanical respiratory support in cardiogenic shock.
    Eur J Heart Fail. 2020;22:168.
    >> Share

    December 2019
  507. TEERLINK JR, Davison BA, Cotter G, Maggioni AP, et al
    Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
    Eur J Heart Fail. 2019 Dec 30. doi: 10.1002/ejhf.1692.
    >> Share

  508. COATS AJS
    Figures of the Heart Failure Association (HFA): Prof. Dr. Tiny Jaarsma, HFA Board Member (2018-2020), Coordinator Patient Care: Management and Delivery Committee and Co-Chair HFA Task Force on Palliative Care.
    Eur J Heart Fail. 2019 Dec 30. doi: 10.1002/ejhf.1705.
    >> Share

  509. PONIKOWSKI P, Kirwan BA, Anker SD, Dorobantu M, et al
    Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
    Eur J Heart Fail. 2019 Dec 28. doi: 10.1002/ejhf.1710.
    >> Share

  510. ANKER MS, von Haehling S, Papp Z, Anker SD, et al
    ESC Heart Failure receives its first impact factor.
    Eur J Heart Fail. 2019 Dec 27. doi: 10.1002/ejhf.1665.
    >> Share

  511. DEVAUX Y, Nossent AY
    A role for m6A RNA methylation in heart failure development?
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1714.
    >> Share

  512. ANKER MS, Hulsmann M, Cleland JG
    What do patients with heart failure die from? A single assassin or a conspiracy?
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1689.
    >> Share

  513. WETTERSTEN N, Horiuchi Y, van Veldhuisen DJ, Mueller C, et al
    Short-term prognostic implications of serum and urine neutrophil gelatinase-associated lipocalin in acute heart failure: findings from the AKINESIS study.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1642.
    >> Share

  514. GOSMANOVA EO, Lyubarova R
    Neutrophil gelatinase-associated lipocalin in acute heart failure: time to move on?
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1684.
    >> Share

  515. MYHRE PL, Vaduganathan M, Greene SJ
    Diagnosing heart failure with preserved ejection fraction in 2019: the search for a gold standard.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1638.
    >> Share

  516. MATHIASEN AB, Qayyum AA, Jorgensen E, Helqvist S, et al
    Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1700.
    >> Share

  517. LARSEN AH, Jessen N, Norrelund H, Tolbod LP, et al
    A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1656.
    >> Share

  518. PATEL PA, Ambrosy AP, Phelan M, Alenezi F, et al
    Association between systolic ejection time and outcomes in heart failure by ejection fraction.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1659.
    >> Share

  519. LAINSCAK M, Milinkovic I, Polovina M, Crespo-Leiro MG, et al
    Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2019 Dec 20. doi: 10.1002/ejhf.1645.
    >> Share

  520. BEUSEKAMP JC, Teng TK, Tay WT, Ouwerkerk W, et al
    Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN-HF registry.
    Eur J Heart Fail. 2019 Dec 18. doi: 10.1002/ejhf.1640.
    >> Share

  521. TENG TK, Cooper L, Tay WT, Luo N, et al
    Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2019 Dec 18. doi: 10.1002/ejhf.1648.
    >> Share

  522. DOCHERTY KF, Shen L, Castagno D, Petrie MC, et al
    Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2019 Dec 17. doi: 10.1002/ejhf.1682.
    >> Share

  523. BERULAVA T, Buchholz E, Elerdashvili V, Pena T, et al
    Changes in m6A RNA methylation contribute to heart failure progression by modulating translation.
    Eur J Heart Fail. 2019 Dec 17. doi: 10.1002/ejhf.1672.
    >> Share

  524. PACKER M
    Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment.
    Eur J Heart Fail. 2019 Dec 17. doi: 10.1002/ejhf.1646.
    >> Share

  525. LIN F, Greenberg B
    Considering the gender gap in heart failure.
    Eur J Heart Fail. 2019 Dec 16. doi: 10.1002/ejhf.1706.
    >> Share

  526. COATS AJS
    Heart Failure Association position papers - a new way to advance the field.
    Eur J Heart Fail. 2019 Dec 16. doi: 10.1002/ejhf.1704.
    >> Share

  527. BHATT AS, Vaduganathan M, Butler J
    Angiotensin-neprilysin inhibition in de novo heart failure - starting off strong.
    Eur J Heart Fail. 2019 Dec 16. doi: 10.1002/ejhf.1675.
    >> Share

  528. KHAN T
    Survival rates in elderly patients with heart failure.
    Eur J Heart Fail. 2019 Dec 16. doi: 10.1002/ejhf.1712.
    >> Share

  529. YANG JH, Obokata M, Reddy YNV, Redfield MM, et al
    Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Dec 15. doi: 10.1002/ejhf.1671.
    >> Share

  530. COATS AJS
    Figures of the Heart Failure Association (HFA): Prof. Dr. Jelena Celutkiene, HFA Board Member (2016-2020) and co-coordinator of the Imaging Study Group of the HFA Diagnosis Committee.
    Eur J Heart Fail. 2019 Dec 12. doi: 10.1002/ejhf.1703.
    >> Share

  531. MORONI A, Viva T, Guazzi M
    Is lung ultrasound monitoring really useful for impacting rehospitalization and mortality in worsening heart failure?
    Eur J Heart Fail. 2019 Dec 12. doi: 10.1002/ejhf.1707.
    >> Share

  532. MOCKEL M, de Boer RA, Slagman AC, von Haehling S, et al
    Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18.
    Eur J Heart Fail. 2019 Dec 12. doi: 10.1002/ejhf.1667.
    >> Share

  533. BAYES-GENIS A, Emdin M, Nunez J
    Biomarker-guided management in acute heart failure: is there light at the end of the tunnel?
    Eur J Heart Fail. 2019 Dec 12. doi: 10.1002/ejhf.1690.
    >> Share

  534. POLOVINA M, Lund LH, Dikic D, Petrovic-Dordevic I, et al
    Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with atrial fibrillation.
    Eur J Heart Fail. 2019 Dec 10. doi: 10.1002/ejhf.1666.
    >> Share

  535. KESHVANI N, Gupta A, Pandey A
    Towards global improvement in heart failure care.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1687.
    >> Share

  536. BOHM M, Slawik J, Brueckmann M, Mattheus M, et al
    Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1663.
    >> Share

  537. PIESKE B, Patel MJ, Westerhout CM, Anstrom KJ, et al
    Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1664.
    >> Share

  538. SENNI M, Wachter R, Witte KK, Straburzynska-Migaj E, et al
    Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1670.
    >> Share

  539. LI L, Liu R, Jiang C, Du X, et al
    Assessing the evidence-practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1630.
    >> Share

  540. SEFEROVIC PM, Coats AJS, Ponikowski P, Filippatos G, et al
    European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1673.
    >> Share

  541. CELUTKIENE J, Lainscak M, Anderson L, Gayat E, et al
    Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1678.
    >> Share

  542. KUAN WS, Ibrahim I, Chan SP, Li Z, et al
    Mid-regional pro-adrenomedullin outperforms N-terminal pro-B-type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation.
    Eur J Heart Fail. 2019 Dec 6. doi: 10.1002/ejhf.1660.
    >> Share

  543. BOMER N, Grote Beverborg N, Hoes MF, Streng KW, et al
    Selenium and outcome in heart failure.
    Eur J Heart Fail. 2019 Dec 6. doi: 10.1002/ejhf.1644.
    >> Share

  544. JANUZZI JL JR, Ibrahim NE
    It is time for consistency in the use of biomarkers in heart failure clinical trials.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1696.
    >> Share

  545. PANDHI P, Ter Maaten JM, Emmens JE, Struck J, et al
    Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1693.
    >> Share

  546. HOES MF, Tromp J, Ouwerkerk W, Bomer N, et al
    The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1674.
    >> Share

  547. KLEIN P, Anker SD, Wechsler A, Skalsky I, et al
    Less invasive ventricular reconstruction for ischaemic heart failure.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1669.
    >> Share

  548. BHATT AS, Vaduganathan M, Patel RB, Fonarow GC, et al
    Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1651.
    >> Share

  549. GARGANI L, Ferre RM, Pang PS
    B-lines in heart failure: will comets guide us?
    Eur J Heart Fail. 2019;21:1616-1618.
    >> Share

    November 2019
  550. O'MEARA E, Allen BG
    Cardiac remodelling patterns and proteomics: the keys to move beyond ejection fraction in heart failure?
    Eur J Heart Fail. 2019 Nov 28. doi: 10.1002/ejhf.1691.
    >> Share

  551. ROVAI S, Corra U, Piepoli M, Vignati C, et al
    Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction.
    Eur J Heart Fail. 2019 Nov 28. doi: 10.1002/ejhf.1595.
    >> Share

  552. INCIARDI RM, Giugliano RP, Claggett B, Gupta DK, et al
    Left atrial structure and function and the risk of death or heart failure in atrial fibrillation.
    Eur J Heart Fail. 2019 Nov 27. doi: 10.1002/ejhf.1606.
    >> Share

  553. LOPEZ-FERNANDEZ T, Lopez-Sendon JL
    Heart failure after treatment for breast cancer: old cancer therapies, new clinical data. What do we need to complete the puzzle?
    Eur J Heart Fail. 2019 Nov 27. doi: 10.1002/ejhf.1662.
    >> Share

  554. MCALISTER FA, Ezekowitz JA, Armstrong PW
    Heart failure treatment and the art of medical decision making.
    Eur J Heart Fail. 2019 Nov 25. doi: 10.1002/ejhf.1655.
    >> Share

  555. WETTERSTEN N, Horiuchi Y, van Veldhuisen DJ, Mueller C, et al
    B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure.
    Eur J Heart Fail. 2019 Nov 25. doi: 10.1002/ejhf.1627.
    >> Share

  556. VAN WOERDEN G, van Veldhuisen DJ, Rienstra M, Westenbrink BD, et al
    Myocardial adiposity in heart failure with preserved ejection fraction: the plot thickens.
    Eur J Heart Fail. 2019 Nov 25. doi: 10.1002/ejhf.1653.
    >> Share

  557. PRIMESSNIG U, Bracic T, Levijoki J, Otsomaa L, et al
    Long-term effects of Na(+) /Ca(2+) exchanger inhibition with ORM-11035 improves cardiac function and remodelling without lowering blood pressure in a model of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Nov 24. doi: 10.1002/ejhf.1619.
    >> Share

  558. KAO D, Purohit S, Jhund P
    Therapeutic futility and phenotypic heterogeneity in heart failure with preserved ejection fraction: what is the role of bionic learning?
    Eur J Heart Fail. 2019 Nov 20. doi: 10.1002/ejhf.1658.
    >> Share

  559. KHAN MS, Irfan S, Khan SU, Mehra MR, et al
    Transforming the interpretation of significance in heart failure trials.
    Eur J Heart Fail. 2019 Nov 14. doi: 10.1002/ejhf.1668.
    >> Share

  560. BOEKEL NB, Duane FK, Jacobse JN, Hauptmann M, et al
    Heart failure after treatment for breast cancer.
    Eur J Heart Fail. 2019 Nov 12. doi: 10.1002/ejhf.1620.
    >> Share

  561. ADLER ED, Voors AA, Klein L, Macheret F, et al
    Improving risk prediction in heart failure using machine learning.
    Eur J Heart Fail. 2019 Nov 12. doi: 10.1002/ejhf.1628.
    >> Share

  562. NAUTA JF, Hummel YM, Tromp J, Ouwerkerk W, et al
    Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment.
    Eur J Heart Fail. 2019 Nov 11. doi: 10.1002/ejhf.1632.
    >> Share

  563. PLATZ E, Solomon SD, McMurray JJV
    Lung ultrasound: monitoring congestion in patients with heart failure.
    Eur J Heart Fail. 2019 Nov 8. doi: 10.1002/ejhf.1636.
    >> Share

  564. CAO TH, Jones DJL, Voors AA, Quinn PA, et al
    Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets.
    Eur J Heart Fail. 2019 Nov 6. doi: 10.1002/ejhf.1608.
    >> Share

  565. ADAMO M, Lombardi CM, Metra M
    November 2019 at a glance. Chronic and acute heart failure: from epidemiology to treatment.
    Eur J Heart Fail. 2019;21:1297-1298.
    >> Share

  566. HAO G, Wang X, Chen Z, Zhang L, et al
    Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015.
    Eur J Heart Fail. 2019;21:1329-1337.
    >> Share

  567. GROENEWEGEN A, Rutten FH
    Decelerating trends in heart failure survival.
    Eur J Heart Fail. 2019;21:1326-1328.
    >> Share

  568. TROMP J, Collins SP
    Dapagliflozin in heart failure: new frontiers.
    Eur J Heart Fail. 2019;21:1412-1414.
    >> Share

    October 2019
  569. RIVAS-LASARTE M, Alvarez-Garcia J, Fernandez-Martinez J, Maestro A, et al
    Lung ultrasound-guided treatment in ambulatory patients with heart failure: a randomized controlled clinical trial (LUS-HF study).
    Eur J Heart Fail. 2019 Oct 31. doi: 10.1002/ejhf.1604.
    >> Share

  570. RAMALHO SHR, Claggett BL, Sweitzer NK, Fang JC, et al
    Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial.
    Eur J Heart Fail. 2019 Oct 31. doi: 10.1002/ejhf.1593.
    >> Share

  571. SULO G, Igland J, Overland S, Egeland GM, et al
    Heart failure in Norway, 2000-2014: analysing incident, total and readmission rates using data from the Cardiovascular Disease in Norway (CVDNOR) Project.
    Eur J Heart Fail. 2019 Oct 23. doi: 10.1002/ejhf.1609.
    >> Share

  572. VITALE C, Jankowska E, Hill L, Piepoli M, et al
    Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure.
    Eur J Heart Fail. 2019 Oct 23. doi: 10.1002/ejhf.1611.
    >> Share

  573. RACHWAN RJ, Butler J, Collins SP, Cotter G, et al
    Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial.
    Eur J Heart Fail. 2019 Oct 23. doi: 10.1002/ejhf.1607.
    >> Share

  574. GO YY, Allen JC Jr, Lam CSP
    Reply: in response to 'Defining a "frequent admitter" phenotype among patients with repeat heart failure admissions' by Go et al.
    Eur J Heart Fail. 2019 Oct 21. doi: 10.1002/ejhf.1622.
    >> Share

  575. SEGAR MW, Patel KV, Ayers C, Basit M, et al
    Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis.
    Eur J Heart Fail. 2019 Oct 21. doi: 10.1002/ejhf.1621.
    >> Share

    September 2019
  576. ANKER SD, Butler J, Filippatos GS, Jamal W, et al
    Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2019 Sep 16. doi: 10.1002/ejhf.1596.
    >> Share

  577. JONES NR, Roalfe AK, Adoki I, Hobbs FDR, et al
    Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis.
    Eur J Heart Fail. 2019 Sep 16. doi: 10.1002/ejhf.1594.
    >> Share

  578. VOORS AA, Bax JJ, Hernandez AF, Wirtz AB, et al
    Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.
    Eur J Heart Fail. 2019 Sep 16. doi: 10.1002/ejhf.1591.
    >> Share

  579. SCHULZ M, Griese-Mammen N, Bohm M, Laufs U, et al
    Letter on 'Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial': reply.
    Eur J Heart Fail. 2019 Sep 16. doi: 10.1002/ejhf.1613.
    >> Share

  580. SEFEROVIC PM, Polovina M
    The eyes are the mirror of the heart: role of retinal microvascular abnormalities in predicting long-term risk of heart failure.
    Eur J Heart Fail. 2019 Sep 11. doi: 10.1002/ejhf.1597.
    >> Share

  581. WU CK, Lee JK, Hsu JC, Su MM, et al
    Myocardial adipose deposition and the development of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Sep 11. doi: 10.1002/ejhf.1617.
    >> Share

  582. KALMANOVICH E, Roubille F, Castet-Nicolas A
    Response to 'Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial'.
    Eur J Heart Fail. 2019 Sep 9. doi: 10.1002/ejhf.1602.
    >> Share

  583. MYHRE PL, Januzzi JL Jr, Butler J, Vaduganathan M, et al
    De novo heart failure: where the journey begins.
    Eur J Heart Fail. 2019 Sep 9. doi: 10.1002/ejhf.1586.
    >> Share

  584. STOLFO D, Uijl A, Benson L, Schrage B, et al
    Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction A propensity score-matched analysis from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2019 Sep 3. doi: 10.1002/ejhf.1615.
    >> Share

  585. COIRO S, Girerd N, Sharma A, Rossignol P, et al
    Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure.
    Eur J Heart Fail. 2019 Sep 2. doi: 10.1002/ejhf.1541.
    >> Share


  586. Corrigendum to 'Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT' [Eur J Heart Fail 2019;21:634-642].
    Eur J Heart Fail. 2019;21:1166.
    >> Share

    August 2019
  587. AIZPURUA AB, Wijk SS, Rocca HB, Henkens M, et al
    Validation of the HFA-PEFF-score for the Diagnosis of Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2019 Aug 31. doi: 10.1002/ejhf.1614.
    >> Share

  588. MARTYN T, Tang WHW
    Can saline repletion be the true TARGET for achieving fluid balance in acute heart failure?
    Eur J Heart Fail. 2019 Aug 29. doi: 10.1002/ejhf.1558.
    >> Share

  589. BLUMER V, Greene SJ, Sun JL, Bart BA, et al
    Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial.
    Eur J Heart Fail. 2019 Aug 27. doi: 10.1002/ejhf.1592.
    >> Share

  590. JAARSMA T, Stromberg A
    We told you so: 'knowledge is not enough to improve heart failure self-care behaviour'.
    Eur J Heart Fail. 2019 Aug 27. doi: 10.1002/ejhf.1580.
    >> Share

  591. KIMMOUN A, Cotter G, Davison B, Takagi K, et al
    Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
    Eur J Heart Fail. 2019 Aug 19. doi: 10.1002/ejhf.1575.
    >> Share

  592. TROMP J, Ferreira JP, Janwanishstaporn S, Shah M, et al
    Heart failure around the world.
    Eur J Heart Fail. 2019 Aug 16. doi: 10.1002/ejhf.1585.
    >> Share

  593. PATEL RB, Nohria A, Butler J, Vaduganathan M, et al
    Dying is not what it used to be! Impact of evolving epidemiology and treatment on mode of death in heart failure.
    Eur J Heart Fail. 2019 Aug 13. doi: 10.1002/ejhf.1587.
    >> Share

  594. COATS AJS
    Figures of the Heart Failure Association (HFA): Prof. Dr. med. Thomas Thum, Chair of the ESC Working Group on Myocardial Function and ex-officio HFA Board Member (2018-2020).
    Eur J Heart Fail. 2019 Aug 13. doi: 10.1002/ejhf.1584.
    >> Share

  595. BOTTLE A, Cowie MR
    Letter in reference to "Defining a 'frequent admitter' phenotype among patients with repeat heart failure admissions".
    Eur J Heart Fail. 2019 Aug 13. doi: 10.1002/ejhf.1590.
    >> Share

  596. AHMAD T, Miller PE, McCullough M, Desai NR, et al
    Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials.
    Eur J Heart Fail. 2019 Aug 13. doi: 10.1002/ejhf.1557.
    >> Share

  597. MIRO O, Garcia Sarasola A, Fuenzalida C, Calderon S, et al
    Departments involved during the first episode of acute heart failure and analysis of emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort.
    Eur J Heart Fail. 2019 Aug 7. doi: 10.1002/ejhf.1567.
    >> Share

  598. TER MAATEN JM, Damman K
    Down the road from challenges in acute heart failure trials.
    Eur J Heart Fail. 2019 Aug 7. doi: 10.1002/ejhf.1571.
    >> Share

  599. MAURICIO R, Patel KV, Agusala V, Singh K, et al
    Sex differences in cardiac function, biomarkers and exercise performance in heart failure with preserved ejection fraction: findings from the RELAX trial.
    Eur J Heart Fail. 2019 Aug 5. doi: 10.1002/ejhf.1554.
    >> Share

  600. VIDAN MT, Martin Sanchez FJ, Sanchez E, Ortiz FJ, et al
    Most elderly patients hospitalized for heart failure lack the abilities needed to perform the tasks required for self-care: impact on outcomes.
    Eur J Heart Fail. 2019 Aug 1. doi: 10.1002/ejhf.1559.
    >> Share

  601. CHIONCEL O, Butler J
    Mid-regional pro-atrial natriuretic peptide for diagnosis of heart failure in non-acute settings: biomarkers plus clinical sense make good sense.
    Eur J Heart Fail. 2019 Aug 1. doi: 10.1002/ejhf.1578.
    >> Share

  602. CHANDRA A, Seidelmann SB, Claggett BL, Klein BE, et al
    The association of retinal vessel calibres with heart failure and long-term alterations in cardiac structure and function: the Atherosclerosis Risk in Communities (ARIC) Study.
    Eur J Heart Fail. 2019 Aug 1. doi: 10.1002/ejhf.1564.
    >> Share

  603. COATS AJS
    Figures of the Heart Failure Association: Dr. Ovidiu Chioncel, HFA Board Member, 2018-2020.
    Eur J Heart Fail. 2019;21:953-954.
    >> Share

    July 2019
  604. MOLINER P, Lupon J, de Antonio M, Domingo M, et al
    Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise.
    Eur J Heart Fail. 2019 Jul 30. doi: 10.1002/ejhf.1569.
    >> Share

  605. ECHOUFFO-TCHEUGUI JB, Masoudi FA, Bao H, Curtis JP, et al
    Body mass index and outcomes of cardiac resynchronization with implantable cardioverter-defibrillator therapy in older patients with heart failure.
    Eur J Heart Fail. 2019 Jul 29. doi: 10.1002/ejhf.1552.
    >> Share

  606. BUNDGAARD JS, Mogensen UM, Christensen S, Ploug U, et al
    The economic burden of heart failure in Denmark from 1998 to 2016.
    Eur J Heart Fail. 2019 Jul 29. doi: 10.1002/ejhf.1577.
    >> Share

  607. HALLEN J, Maggioni AP, Lopez-De-Sa E, Turazza FM, et al
    Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial.
    Eur J Heart Fail. 2019 Jul 29. doi: 10.1002/ejhf.1574.
    >> Share

  608. YAZAKI Y, Salzano A, Nelson CP, Voors AA, et al
    Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis.
    Eur J Heart Fail. 2019 Jul 28. doi: 10.1002/ejhf.1550.
    >> Share

  609. PIEPOLI MF, Binno S, Coats AJS, Cohen-Solal A, et al
    Regional differences in exercise training implementation in heart failure: findings from the Exercise Training in Heart Failure (ExTraHF) survey.
    Eur J Heart Fail. 2019 Jul 25. doi: 10.1002/ejhf.1538.
    >> Share

  610. DISERTORI M, Mase M, Rigoni M, Nollo G, et al
    Heart failure patients unresponsive to implantable cardioverter-defibrillator therapy: a neglected problem.
    Eur J Heart Fail. 2019 Jul 22. doi: 10.1002/ejhf.1551.
    >> Share

  611. MYHRE PL, Vaduganathan M, Claggett BL, Lam CSP, et al
    Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial.
    Eur J Heart Fail. 2019 Jul 22. doi: 10.1002/ejhf.1542.
    >> Share

  612. WIGGERS H
    Insulin treatment in heart failure patients: the good, the bad or the ugly?
    Eur J Heart Fail. 2019 Jul 22. doi: 10.1002/ejhf.1556.
    >> Share

  613. PACKER M, Butler J, Filippatos GS, Jamal W, et al
    Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Eur J Heart Fail. 2019 Jul 16. doi: 10.1002/ejhf.1536.
    >> Share

  614. MCMURRAY JJV, DeMets DL, Inzucchi SE, Kober L, et al
    The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.
    Eur J Heart Fail. 2019 Jul 15. doi: 10.1002/ejhf.1548.
    >> Share

  615. FRIGERIO M, Carugo S, Voltolini A
    Of hearts, minds, and guts: difficulties in diagnosing heart failure in the young.
    Eur J Heart Fail. 2019 Jul 15. doi: 10.1002/ejhf.1544.
    >> Share

  616. XANTHOPOULOS A, Papamichalis M, Zajichek A, Milinovich A, et al
    In-hospital red blood cell distribution width change in patients with heart failure.
    Eur J Heart Fail. 2019 Jul 4. doi: 10.1002/ejhf.1546.
    >> Share

  617. HANSEN D
    Access to exercise-based rehabilitation across Europe for patients with heart failure: where evidence-based practice is hampered by lacking resources.
    Eur J Heart Fail. 2019 Jul 4. doi: 10.1002/ejhf.1545.
    >> Share

  618. BARTHELMES J, Nagele MP, Cantatore S, Novruzov E, et al
    Retinal microvascular dysfunction in patients with coronary artery disease with and without heart failure: a continuum?
    Eur J Heart Fail. 2019 Jul 4. doi: 10.1002/ejhf.1537.
    >> Share

  619. SHEN L, Rorth R, Cosmi D, Kristensen SL, et al
    Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Jul 4. doi: 10.1002/ejhf.1535.
    >> Share

    June 2019
  620. BAUERSACHS J, Konig T, van der Meer P, Petrie MC, et al
    Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy.
    Eur J Heart Fail. 2019 Jun 27. doi: 10.1002/ejhf.1493.
    >> Share

  621. PLATZ E, Jhund PS, Girerd N, Pivetta E, et al
    Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure.
    Eur J Heart Fail. 2019 Jun 19. doi: 10.1002/ejhf.1499.
    >> Share

  622. ABRAHAM WT, Ponikowski P, Brueckmann M, Zeller C, et al
    Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
    Eur J Heart Fail. 2019 Jun 19. doi: 10.1002/ejhf.1486.
    >> Share

  623. AMBROSY AP, DeVore AD, Velazquez EJ
    In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time.
    Eur J Heart Fail. 2019 Jun 19. doi: 10.1002/ejhf.1540.
    >> Share

  624. GOHAR A, Rutten FH, den Ruijter H, Kelder JC, et al
    Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure.
    Eur J Heart Fail. 2019 Jun 17. doi: 10.1002/ejhf.1495.
    >> Share

  625. CAO J, Koay YC, Quek LE, Parker B, et al
    Myocardial substrate changes in advanced ischaemic and advanced dilated human heart failure.
    Eur J Heart Fail. 2019 Jun 11. doi: 10.1002/ejhf.1479.
    >> Share

  626. FELKER GM, Borentain M, Cleland JG, DeSouza MM, et al
    Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.
    Eur J Heart Fail. 2019 Jun 6. doi: 10.1002/ejhf.1504.
    >> Share

  627. MUELLER C, McDonald K, de Boer RA, Maisel A, et al
    Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations.
    Eur J Heart Fail. 2019;21:715-731.
    >> Share

    May 2019
  628. PACKER M
    Major reduction in the risk of sudden cardiac death in patients with chronic heart failure with the use of drug and device combinations that favourably affect left ventricular structure.
    Eur J Heart Fail. 2019 May 29. doi: 10.1002/ejhf.1501.
    >> Share

  629. WACHTER R, Senni M, Belohlavek J, Straburzynska-Migaj E, et al
    Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.
    Eur J Heart Fail. 2019 May 27. doi: 10.1002/ejhf.1498.
    >> Share

  630. KAPELIOS CJ, Lainscak M, Savarese G, Laroche C, et al
    Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long-Term Registry: bridging between EMA/FDA label, the PARADIGM-HF trial, ESC Guidelines, and real-world.
    Eur J Heart Fail. 2019 May 27. doi: 10.1002/ejhf.1532.
    >> Share

  631. SEFEROVIC PM, Ponikowski P, Anker SD, Bauersachs J, et al
    Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2019 May 26. doi: 10.1002/ejhf.1531.
    >> Share

  632. MOCKEL M, Koehler K, Anker SD, Vollert J, et al
    Biomarker Guidance allows a more personalized allocation of patients for Remote Patient Management in Heart Failure Results from the TIM-HF2 Trial.
    Eur J Heart Fail. 2019 May 25. doi: 10.1002/ejhf.1530.
    >> Share

  633. SCHULZ M, Griese-Mammen N, Anker SD, Koehler F, et al
    Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial.
    Eur J Heart Fail. 2019 May 25. doi: 10.1002/ejhf.1503.
    >> Share

  634. CHIONCEL O, Mebazaa A, Maggioni AP, Harjola VP, et al
    Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2019 May 24. doi: 10.1002/ejhf.1492.
    >> Share

  635. JAVALOYES P, Miro O, Gil V, Martin-Sanchez FJ, et al
    Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes.
    Eur J Heart Fail. 2019 May 24. doi: 10.1002/ejhf.1502.
    >> Share

  636. BIEGUS J, Zymlinski R, Siwolowski P, Testani J, et al
    Controlled decongestion by Reprieve Therapy in acute heart failure: the results of the TARGET-1 and TARGET-2 Studies.
    Eur J Heart Fail. 2019 May 24. doi: 10.1002/ejhf.1533.
    >> Share

  637. DOEHNER W, von Haehling S
    Intravenous iron supplementation is state of the art therapy in patients with heart failure and iron deficiency.
    Eur J Heart Fail. 2019 May 22. doi: 10.1002/ejhf.1496.
    >> Share

  638. SENNI M, Adamo M, Metra M, Alfieri O, et al
    Treatment of functional mitral regurgitation in chronic heart failure: can we get a 'proof of concept' from the MITRA-FR and COAPT trials?
    Eur J Heart Fail. 2019 May 22. doi: 10.1002/ejhf.1491.
    >> Share

  639. SEFEROVIC PM, Seferovic JP, Polovina MM
    Diving into the unknown: sodium-glucose cotransporter-2 inhibitors in heart failure without diabetes.
    Eur J Heart Fail. 2019 May 21. doi: 10.1002/ejhf.1500.
    >> Share

  640. MARKOUSIS-MAVROGENIS G, Tromp J, Ouwerkerk W, Devalaraja M, et al
    The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study.
    Eur J Heart Fail. 2019 May 14. doi: 10.1002/ejhf.1482.
    >> Share

  641. VERBRUGGE FH, Martens P, Ameloot K, Haemels V, et al
    Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance.
    Eur J Heart Fail. 2019 May 9. doi: 10.1002/ejhf.1478.
    >> Share

  642. MULLENS W, Damman K
    Response to letters on "The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology".
    Eur J Heart Fail. 2019 May 7. doi: 10.1002/ejhf.1477.
    >> Share

  643. COATS AJS
    Figures of the Heart Failure Association: Professor Dr. med. Johann Bauersachs, Chair of the Clinical Science Section.
    Eur J Heart Fail. 2019;21:545-548.
    >> Share

  644. COATS AJS
    The first heart failure meeting in the Republic of Kazakhstan.
    Eur J Heart Fail. 2019;21:549.
    >> Share

  645. COATS AJS
    HFA Committee on Comorbidities - report of a meeting on physiological monitoring in the complex multi-morbid heart failure patient.
    Eur J Heart Fail. 2019;21:543-544.
    >> Share


  646. Abstracts of the Heart Failure 2019 and the World Congress on Acute Heart Failure, 25-28 May 2019, Megaron Athens International Conference Centre, Greece.
    Eur J Heart Fail. 2019;21 Suppl 1:3-592.
    >> Share

    April 2019
  647. CHIA YMF, Teng TK, Tay WT, Anand I, et al
    Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus.
    Eur J Heart Fail. 2019 Apr 29. doi: 10.1002/ejhf.1467.
    >> Share

  648. KOZHUHAROV N, Sabti Z, Wussler D, Nowak A, et al
    Prospective validation of N-terminal pro B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure.
    Eur J Heart Fail. 2019 Apr 24. doi: 10.1002/ejhf.1471.
    >> Share

  649. PACKER M
    Disproportionate functional mitral regurgitation: a new therapeutic target in patients with heart failure and a reduced ejection fraction.
    Eur J Heart Fail. 2019 Apr 24. doi: 10.1002/ejhf.1469.
    >> Share

  650. BUTLER J, Khan MS, Anker SD
    Novel potassium binders as enabling therapy in heart failure.
    Eur J Heart Fail. 2019 Apr 16. doi: 10.1002/ejhf.1474.
    >> Share

  651. SEFEROVIC PM, Polovina M, Bauersachs J, Arad M, et al
    Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2019 Apr 16. doi: 10.1002/ejhf.1461.
    >> Share

  652. UIJL A, Lund LH, Savarese G
    The GUIDE-IT heart failure risk prediction model: another fish in the sea?
    Eur J Heart Fail. 2019 Apr 14. doi: 10.1002/ejhf.1472.
    >> Share

  653. SUDHAKARAN S, McCullough PA
    Common laboratory parameters as indicators of multi-organ dysfunction in acute heart failure.
    Eur J Heart Fail. 2019 Apr 11. doi: 10.1002/ejhf.1466.
    >> Share

  654. AHMAD FA, Petrie MC, McMurray JJV, Lang NN, et al
    Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it.
    Eur J Heart Fail. 2019 Apr 11. doi: 10.1002/ejhf.1463.
    >> Share

  655. DONG Y, Teo SY, Kang K, Tan M, et al
    Cognitive impairment in Asian patients with heart failure: prevalence, biomarkers, clinical correlates, and outcomes.
    Eur J Heart Fail. 2019 Apr 2. doi: 10.1002/ejhf.1442.
    >> Share

  656. PILICHOU K, Basso C
    Heart failure in arrhythmogenic cardiomyopathy: is phenotypic variability just a matter of genetics?
    Eur J Heart Fail. 2019 Apr 1. doi: 10.1002/ejhf.1456.
    >> Share

  657. KOMAJDA M, Schope J, Wagenpfeil S, Tavazzi L, et al
    Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.
    Eur J Heart Fail. 2019 Apr 1. doi: 10.1002/ejhf.1459.
    >> Share

  658. PANDEY A, Patel KV, Ayers C, Tang WHW, et al
    Temporal association between hospitalization event and subsequent risk of mortality among patients with stable chronic heart failure with preserved ejection fraction: insights from the TOPCAT trial.
    Eur J Heart Fail. 2019 Apr 1. doi: 10.1002/ejhf.1460.
    >> Share

  659. METRA M
    April 2019 at a glance: prediction of heart failure, left atrial function, cardio-oncology.
    Eur J Heart Fail. 2019;21:393-394.
    >> Share

  660. COATS AJS
    Heart Failure Atlas, a major project of the Heart Failure Association in concert with the European Society of Cardiology.
    Eur J Heart Fail. 2019;21:395-397.
    >> Share

    March 2019
  661. REDDY YNV, Obokata M, Egbe A, Yang JH, et al
    Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Mar 28. doi: 10.1002/ejhf.1464.
    >> Share

  662. O'CONNOR C, Fiuzat M, Mulder H, Coles A, et al
    Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score.
    Eur J Heart Fail. 2019 Mar 27. doi: 10.1002/ejhf.1450.
    >> Share

  663. WESSLER BS, McCauley M, Morine K, Konstam MA, et al
    Relation between therapy-induced changes in natriuretic peptide levels and long-term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2019 Mar 27. doi: 10.1002/ejhf.1411.
    >> Share

  664. MULLENS W, Damman K
    Reply to letters on "The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology".
    Eur J Heart Fail. 2019 Mar 22. doi: 10.1002/ejhf.1462.
    >> Share

  665. TEMPORELLI PL, Tilz RR, Arbelo E, Dagres N, et al
    Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association.
    Eur J Heart Fail. 2019 Mar 21. doi: 10.1002/ejhf.1458.
    >> Share

  666. MCMURRAY JJV, DeMets DL, Inzucchi SE, Kober L, et al
    A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
    Eur J Heart Fail. 2019 Mar 21. doi: 10.1002/ejhf.1432.
    >> Share

  667. BAVENDIEK U, Berliner D, Davila LA, Schwab J, et al
    Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study.
    Eur J Heart Fail. 2019 Mar 20. doi: 10.1002/ejhf.1452.
    >> Share

  668. TRULLAS JC, Formiga F, Manzano L
    The use of thiazide and thiazide-like diuretics in heart failure with congestion.
    Eur J Heart Fail. 2019 Mar 20. doi: 10.1002/ejhf.1455.
    >> Share

  669. RICHARDS AM, Pemberton C, Yandle T
    How does neprilysin inhibition in heart failure work?
    Eur J Heart Fail. 2019 Mar 18. doi: 10.1002/ejhf.1454.
    >> Share

  670. GHAFOURIAN K, Chang HC, Ardehali H
    Intravenous iron therapy in heart failure: a different perspective.
    Eur J Heart Fail. 2019 Mar 18. doi: 10.1002/ejhf.1434.
    >> Share

  671. ESCOBAR C, Manzano L
    Mineralocorticoid receptor antagonists and acute heart failure.
    Eur J Heart Fail. 2019 Mar 12. doi: 10.1002/ejhf.1453.
    >> Share

  672. IKONOMIDIS I, Aboyans V, Blacher J, Brodmann M, et al
    The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascula
    Eur J Heart Fail. 2019 Mar 12. doi: 10.1002/ejhf.1436.
    >> Share

  673. SQUIRE I
    Measurement of circulating natriuretic peptides to identify community-based patients at risk of incident heart failure - should we?
    Eur J Heart Fail. 2019 Mar 8. doi: 10.1002/ejhf.1391.
    >> Share

  674. TER MAATEN JM, Kremer D, Demissei BG, Struck J, et al
    Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.
    Eur J Heart Fail. 2019 Mar 6. doi: 10.1002/ejhf.1437.
    >> Share

  675. PACKER M
    Electrophysiological interventions in the treatment of chronic heart failure: a comparison of the strength of evidence supporting cardiac resynchronization for electrical conduction delay and catheter ablation for atrial fibrillation.
    Eur J Heart Fail. 2019 Mar 6. doi: 10.1002/ejhf.1447.
    >> Share

  676. PEREIRA NL, Desai VK, Jaffe AS
    Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas a cause du BNP?
    Eur J Heart Fail. 2019 Mar 4. doi: 10.1002/ejhf.1451.
    >> Share

  677. PAVO N, Gugerell A, Goliasch G, Bartko PE, et al
    Increased granulocyte membrane neprilysin (CD10) expression is associated with better prognosis in heart failure.
    Eur J Heart Fail. 2019 Mar 3. doi: 10.1002/ejhf.1441.
    >> Share

  678. COATS AJS, Seferovic PM
    News from the American Heart Association: more on sodium-glucose co-transporter 2 inhibitors, diabetes and heart failure.
    Eur J Heart Fail. 2019;21:261-263.
    >> Share

  679. METRA M
    Figures of the Heart Failure Association: Andrew J. Stewart Coats, President-Elect, 2018-2020.
    Eur J Heart Fail. 2019;21:269-271.
    >> Share

  680. PAPADAKI A, Martinez-Gonzalez MA, Alonso-Gomez A, Rekondo J, et al
    Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial. Eur J Heart Fail 2017;19:1179-1185. doi: 10.1002/ejhf.750.
    Eur J Heart Fail. 2019;21:389-391.
    >> Share

  681. COATS AJS
    Figures of the Heart Failure Association: Petar M. Seferovic, President, 2018-2020.
    Eur J Heart Fail. 2019;21:266-268.
    >> Share

  682. TER MAATEN JM
    Unravelling the effect of sacubitril/valsartan on loop diuretic dosing.
    Eur J Heart Fail. 2019;21:342-344.
    >> Share

  683. HAWKINS NM
    Cardiac resynchronization therapy improves survival in selected patients with moderately impaired ejection fraction - the importance of left ventricular remodelling.
    Eur J Heart Fail. 2019;21:370-372.
    >> Share

  684. METRA M
    March 2019 at a glance: epidemiology and clinical trials.
    Eur J Heart Fail. 2019;21:259-260.
    >> Share

  685. FERREIRA JP, Abreu P, McMurray JJV, van Veldhuisen DJ, et al
    Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial.
    Eur J Heart Fail. 2019;21:345-351.
    >> Share

  686. VARDENY O, Claggett B, Kachadourian J, Desai AS, et al
    Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
    Eur J Heart Fail. 2019;21:337-341.
    >> Share

  687. AMBROSY AP, Stevens SR, Al-Khalidi HR, Rouleau JL, et al
    Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy.
    Eur J Heart Fail. 2019;21:373-381.
    >> Share

  688. BUCKLEY LF, Canada JM, Carbone S, Trankle CR, et al
    Potential role for interleukin-1 in the cardio-renal syndrome.
    Eur J Heart Fail. 2019;21:385-386.
    >> Share

  689. KUTYIFA V, Vermilye K, Solomon SD, McNitt S, et al
    Long-term outcomes of cardiac resynchronization therapy by left ventricular ejection fraction.
    Eur J Heart Fail. 2019;21:360-369.
    >> Share

    February 2019
  690. KUNUTSOR SK, Laukkanen JA
    Heart failure risk reduction: is fit and overweight or obese better than unfit and normal weight?
    Eur J Heart Fail. 2019 Feb 27. doi: 10.1002/ejhf.1440.
    >> Share

  691. HERMIDA A, Fressart V, Hidden-Lucet F, Donal E, et al
    High risk of heart failure associated with desmoglein-2 mutations compared to plakophilin-2 mutations in arrhythmogenic right ventricular cardiomyopathy/dysplasia.
    Eur J Heart Fail. 2019 Feb 21. doi: 10.1002/ejhf.1423.
    >> Share

  692. KOKKINOS P, Faselis C, Franklin B, Lavie CJ, et al
    Cardiorespiratory fitness, body mass index and heart failure incidence.
    Eur J Heart Fail. 2019 Feb 19. doi: 10.1002/ejhf.1433.
    >> Share

  693. KRISTENSEN SL
    Individualizing surgical revascularization in patients with ischaemic heart failure - a further dive into STICHES.
    Eur J Heart Fail. 2019 Feb 18. doi: 10.1002/ejhf.1426.
    >> Share

  694. GIRERD N, Platz E
    Beyond clinical examination and natriuretic peptides: comprehensive quantification of congestion with ultrasound in ambulatory heart failure patients.
    Eur J Heart Fail. 2019 Feb 18. doi: 10.1002/ejhf.1422.
    >> Share

  695. BIEGUS J, Zymlinski R, Sokolski M, Todd J, et al
    Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure.
    Eur J Heart Fail. 2019 Feb 17. doi: 10.1002/ejhf.1428.
    >> Share

  696. JANUZZI J, Ferreira JP, Bohm M, Kaul S, et al
    Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.
    Eur J Heart Fail. 2019 Feb 14. doi: 10.1002/ejhf.1419.
    >> Share

  697. OBOKATA M, Borlaug BA
    Left atrial dysfunction: the next key target in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Feb 8. doi: 10.1002/ejhf.1420.
    >> Share

  698. AMBROSY AP, Lee KK
    Applying data science approaches to identify frequent flyers in heart failure: rise of the machines.
    Eur J Heart Fail. 2019 Feb 7. doi: 10.1002/ejhf.1387.
    >> Share

  699. DE BOER RA, De Keulenaer G, Bauersachs J, Brutsaert D, et al
    Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology.
    Eur J Heart Fail. 2019 Feb 4. doi: 10.1002/ejhf.1406.
    >> Share

  700. GRODIN JL, Philips S, Mullens W, Nijst P, et al
    Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.
    Eur J Heart Fail. 2019 Feb 4. doi: 10.1002/ejhf.1407.
    >> Share

  701. USSIA GP
    'Finding the biomarker' for transcatheter mitral valve repair.
    Eur J Heart Fail. 2019;21:193-195.
    >> Share

  702. PIGHI M, Benfari G, Pesarini G, Ribichini F, et al
    Transcatheter edge-to-edge mitral valve repair: what is the measure of success?
    Eur J Heart Fail. 2019;21:205-207.
    >> Share

  703. METRA M
    February 2019 at a glance: pathophysiology, exercise capacity, diuretics and valve disease.
    Eur J Heart Fail. 2019;21:135-136.
    >> Share

  704. PACKER M
    The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range.
    Eur J Heart Fail. 2019;21:156-162.
    >> Share

  705. BLANKINSHIP D, Katz MR, Lozonschi L, Tedford RJ, et al
    Pulmonary artery wedge pressure respiratory variation is correlated with haemodynamic improvement with increased left ventricular assist system speed.
    Eur J Heart Fail. 2019;21:251-253.
    >> Share

    January 2019
  706. SARTIPY U, Savarese G, Dahlstrom U, Fu M, et al
    Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Jan 30. doi: 10.1002/ejhf.1389.
    >> Share

  707. RIENSTRA M, Kotecha D, van Veldhuisen DJ
    Heart rate in patients with atrial fibrillation and heart failure with preserved ejection fraction: a prognosticator like in sinus rhythm?
    Eur J Heart Fail. 2019 Jan 30. doi: 10.1002/ejhf.1425.
    >> Share

  708. BISTOLA V, Polyzogopoulou E, Ikonomidis I, Parissis J, et al
    Lung ultrasound for the diagnosis of acute heart failure: time to upgrade current indication?
    Eur J Heart Fail. 2019 Jan 28. doi: 10.1002/ejhf.1414.
    >> Share

  709. STOCKER TJ, Scheck F, Orban M, Braun D, et al
    Physical activity tracking in correlation to conventional heart failure monitoring assessing improvements after transcatheter mitral and tricuspid valve repair.
    Eur J Heart Fail. 2019 Jan 28. doi: 10.1002/ejhf.1418.
    >> Share

  710. PIVETTA E, Goffi A, Nazerian P, Castagno D, et al
    Lung ultrasound integrated with clinical assessment for the diagnosis of acute decompensated heart failure in the emergency department: a randomized controlled trial.
    Eur J Heart Fail. 2019 Jan 28. doi: 10.1002/ejhf.1379.
    >> Share

  711. KALOGEROPOULOS AP, Butler J
    The other serelaxin in acute heart failure study: lessons from a pragmatic clinical trial.
    Eur J Heart Fail. 2019 Jan 28. doi: 10.1002/ejhf.1416.
    >> Share

  712. PELLICORI P, Shah P, Cuthbert J, Urbinati A, et al
    Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure.
    Eur J Heart Fail. 2019 Jan 22. doi: 10.1002/ejhf.1383.
    >> Share

  713. NAGAI M, Forster CY, Dote K, Shimokawa H, et al
    Sex hormones in heart failure revisited?
    Eur J Heart Fail. 2019 Jan 22. doi: 10.1002/ejhf.1408.
    >> Share

  714. CAMPBELL DJ, Gong FF, Jelinek MV, Castro JM, et al
    Prediction of incident heart failure by serum amino-terminal pro-B-type natriuretic peptide level in a community-based cohort.
    Eur J Heart Fail. 2019 Jan 18. doi: 10.1002/ejhf.1381.
    >> Share

  715. ANKER SD, Borggrefe M, Neuser H, Ohlow MA, et al
    Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2019 Jan 16. doi: 10.1002/ejhf.1374.
    >> Share

  716. TELLES F, Nanayakkara S, Evans S, Patel HC, et al
    Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Jan 16. doi: 10.1002/ejhf.1399.
    >> Share

  717. PAOLILLO S, Veglia F, Salvioni E, Corra U, et al
    Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years.
    Eur J Heart Fail. 2019 Jan 11. doi: 10.1002/ejhf.1364.
    >> Share

  718. CHIONCEL O, Ambrosy AP
    Trimethylamine N-oxide and risk of heart failure progression: marker or mediator of disease.
    Eur J Heart Fail. 2019 Jan 9. doi: 10.1002/ejhf.1409.
    >> Share

  719. UIJL A, Koudstaal S, Direk K, Denaxas S, et al
    Risk factors for incident heart failure in age- and sex-specific strata: a population-based cohort using linked electronic health records.
    Eur J Heart Fail. 2019 Jan 7. doi: 10.1002/ejhf.1350.
    >> Share

  720. MAGGIONI AP, Lopez-Sendon J, Nielsen OW, Hallen J, et al
    Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.
    Eur J Heart Fail. 2019 Jan 2. doi: 10.1002/ejhf.1368.
    >> Share

  721. MULLENS W, Damman K, Harjola VP, Mebazaa A, et al
    The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2019 Jan 1. doi: 10.1002/ejhf.1369.
    >> Share

  722. FERREIRA JP, Metra M, Anker SD, Dickstein K, et al
    Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study.
    Eur J Heart Fail. 2019 Jan 1. doi: 10.1002/ejhf.1380.
    >> Share

  723. AHMAD T, Freeman JV, Asselbergs FW
    Can advanced analytics fix modern medicine's problem of uncertainty, imprecision, and inaccuracy?
    Eur J Heart Fail. 2019;21:86-89.
    >> Share

  724. MEHRA MR
    Evolving disruption in left ventricular assist systems: forgiving but not yet forgettable.
    Eur J Heart Fail. 2019;21:98-100.
    >> Share

  725. LUND LH
    Improving long-term outcomes with left ventricular assist devices-referral, selection, experience, and technology.
    Eur J Heart Fail. 2019;21:101-102.
    >> Share

  726. FERREIRA JP, Zannad F
    Patient-reported and morbidity-mortality endpoints: can one have the best of both worlds?
    Eur J Heart Fail. 2019;21:71-73.
    >> Share

  727. VAN KEER JM, Vanassche T, Droogne W, Rex S, et al
    Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation.
    Eur J Heart Fail. 2019;21:129-131.
    >> Share

  728. CERISANO G, Buonamici P, Migliorini A, Santini A, et al
    Relation between post-myocardial infarct remodelling and gelatinase activity in patients enrolled in the TIPTOP trial.
    Eur J Heart Fail. 2019;21:127-129.
    >> Share

  729. METRA M
    January 2019 at a glance: prognostic assessment, left ventricular assist devices, disease management and quality of care.
    Eur J Heart Fail. 2019;21:1-2.
    >> Share

    December 2018
  730. PIEPOLI MF
    E-health in self-care of heart failure patients: promises become reality.
    Eur J Heart Fail. 2018 Dec 28. doi: 10.1002/ejhf.1386.
    >> Share

  731. VOORS AA, Kremer D, Geven C, Ter Maaten JM, et al
    Adrenomedullin in heart failure: pathophysiology and therapeutic application.
    Eur J Heart Fail. 2018 Dec 28. doi: 10.1002/ejhf.1366.
    >> Share

  732. KEANE C, McClelland S, Gallagher J, O'Reilly O, et al
    The Heart Failure Virtual Consultation - a powerful tool for the delivery of specialist care and the democratization of knowledge in the community.
    Eur J Heart Fail. 2018 Dec 28. doi: 10.1002/ejhf.1390.
    >> Share

  733. AMBROSETTI M, La Rovere MT, Scalvini S, Pedretti RFE, et al
    Cardiac rehabilitation in heart failure after the ExTraMATCH II study: who still believes?
    Eur J Heart Fail. 2018 Dec 28. doi: 10.1002/ejhf.1388.
    >> Share

  734. PATEL RB, Warraich HJ, Butler J, Vaduganathan M, et al
    Surprise, surprise: improving the referral pathway to palliative care interventions in advanced heart failure.
    Eur J Heart Fail. 2018 Dec 28. doi: 10.1002/ejhf.1382.
    >> Share

  735. MANSOURI I, Allodji RS, Hill C, El-Fayech C, et al
    The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer.
    Eur J Heart Fail. 2018 Dec 27. doi: 10.1002/ejhf.1376.
    >> Share

  736. ZYMLINSKI R, Sokolski M, Biegus J, Siwolowski P, et al
    Multi-organ dysfunction/injury on admission identifies acute heart failure patients at high risk of poor outcome.
    Eur J Heart Fail. 2018 Dec 18. doi: 10.1002/ejhf.1378.
    >> Share

  737. GO YY, Sellmair R, Allen JC Jr, Sahlen A, et al
    Defining a 'frequent admitter' phenotype among patients with repeat heart failure admissions.
    Eur J Heart Fail. 2018 Dec 13. doi: 10.1002/ejhf.1348.
    >> Share

  738. STRAW S, Byrom R, Gierula J, Paton MF, et al
    Predicting one-year mortality in heart failure using the 'Surprise Question': a prospective pilot study.
    Eur J Heart Fail. 2018 Dec 11. doi: 10.1002/ejhf.1353.
    >> Share

  739. CHANDRAMOULI C, Teng TK, Tay WT, Yap J, et al
    Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry.
    Eur J Heart Fail. 2018 Dec 10. doi: 10.1002/ejhf.1358.
    >> Share

  740. RORTH R, Jhund PS, Kristensen SL, Desai AS, et al
    The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.
    Eur J Heart Fail. 2018 Dec 10. doi: 10.1002/ejhf.1359.
    >> Share

  741. MARTI CN, Fonarow GC, Anker SD, Yancy C, et al
    Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges.
    Eur J Heart Fail. 2018 Dec 10. doi: 10.1002/ejhf.1351.
    >> Share

  742. DEWAN P, Jhund PS, Shen L, Petrie MC, et al
    Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas.
    Eur J Heart Fail. 2018 Dec 10. doi: 10.1002/ejhf.1347.
    >> Share

  743. NOUGUE H, Pezel T, Picard F, Sadoune M, et al
    Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
    Eur J Heart Fail. 2018 Dec 6. doi: 10.1002/ejhf.1342.
    >> Share

  744. GROENEWEGEN A, Rutten FH
    Near-home heart failure care.
    Eur J Heart Fail. 2018 Dec 6. doi: 10.1002/ejhf.1345.
    >> Share

  745. ANKER MS, von Haehling S, Papp Z, Anker SD, et al
    The new Heart Failure Association journal - ESC Heart Failure.
    Eur J Heart Fail. 2018;20:1657-1663.
    >> Share

  746. FARMAKIS D, Keramida K, Filippatos G
    How to build a cardio-oncology service?
    Eur J Heart Fail. 2018;20:1732-1734.
    >> Share

  747. FUSSNER LA, Karlstedt E, Hodge DO, Fine NM, et al
    Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres.
    Eur J Heart Fail. 2018;20:1713-1720.
    >> Share

  748. NAUTA JF, Jin X, Hummel YM, Voors AA, et al
    Markers of left ventricular systolic dysfunction when left ventricular ejection fraction is normal.
    Eur J Heart Fail. 2018;20:1636-1638.
    >> Share

    November 2018
  749. WAGENAAR KP, Broekhuizen BDL, Jaarsma T, Kok I, et al
    Effectiveness of the European Society of Cardiology/Heart Failure Association website 'heartfailurematters.org' and an e-health adjusted care pathway in patients with stable heart failure: results of the 'e-Vita HF' randomized controlled trial.
    Eur J Heart Fail. 2018 Nov 28. doi: 10.1002/ejhf.1354.
    >> Share

  750. TSCHOPE C, Kherad B, Klein O, Lipp A, et al
    Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond.
    Eur J Heart Fail. 2018 Nov 28. doi: 10.1002/ejhf.1349.
    >> Share

  751. ADAMOPOULOS S, Corra U, Laoutaris ID, Pistono M, et al
    Exercise training in patients with ventricular assist devices: a review of the evidence and practical advice. A position paper from the Committee on Exercise Physiology and Training and the Committee of Advanced Heart Failure of the Heart Failure Asso
    Eur J Heart Fail. 2018 Nov 26. doi: 10.1002/ejhf.1352.
    >> Share

  752. GEVAERT AB, Beckers PJ, Van Craenenbroeck AH, Lemmens K, et al
    Endothelial dysfunction and cellular repair in heart failure with preserved ejection fraction: response to a single maximal exercise bout.
    Eur J Heart Fail. 2018 Nov 23. doi: 10.1002/ejhf.1339.
    >> Share

  753. SENNI M, Iorio A, Seferovic P
    Heart failure with preserved ejection fraction in Asia: the far side of the moon?
    Eur J Heart Fail. 2018 Nov 23. doi: 10.1002/ejhf.1335.
    >> Share

  754. PARATI G, Ochoa JE
    Prognostic value of baroreflex sensitivity in heart failure. A 2018 reappraisal.
    Eur J Heart Fail. 2018 Nov 23. doi: 10.1002/ejhf.1334.
    >> Share

  755. GREENE SJ, Fonarow GC, Solomon SD, Subacius HP, et al
    Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial.
    Eur J Heart Fail. 2018 Nov 11. doi: 10.1002/ejhf.1310.
    >> Share

  756. CELUTKIENE J, Plymen CM, Flachskampf FA, de Boer RA, et al
    Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2018 Nov 9. doi: 10.1002/ejhf.1330.
    >> Share

  757. GREENE SJ, Felker GM, Butler J
    Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care.
    Eur J Heart Fail. 2018 Nov 5. doi: 10.1002/ejhf.1341.
    >> Share

  758. METRA M
    November 2018 at a glance: from prediction of heart failure in asymptomatic subjects to advanced chronic heart failure.
    Eur J Heart Fail. 2018;20:1503-1504.
    >> Share

  759. FLINT K
    Frailty in TOPCAT: a deep dive into the deficit index approach for defining frailty.
    Eur J Heart Fail. 2018;20:1578-1579.
    >> Share

  760. GORI M, Redfield MM, Calabrese A, Canova P, et al
    Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study.
    Eur J Heart Fail. 2018;20:1540-1548.
    >> Share

  761. SANDERS NA, Supiano MA, Lewis EF, Liu J, et al
    The frailty syndrome and outcomes in the TOPCAT trial.
    Eur J Heart Fail. 2018;20:1570-1577.
    >> Share

    October 2018
  762. SUZUKI T, Yazaki Y, Voors AA, Jones DJL, et al
    Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure (from BIOSTAT-CHF).
    Eur J Heart Fail. 2018 Oct 29. doi: 10.1002/ejhf.1338.
    >> Share

  763. COWIE MR, Gallagher AM, Simonds AK
    Treating central sleep apnoea in heart failure: is pull better than push?
    Eur J Heart Fail. 2018 Oct 23. doi: 10.1002/ejhf.1337.
    >> Share

  764. VAN DER POL A, van Gilst WH, Voors AA, van der Meer P, et al
    Treating oxidative stress in heart failure: past, present and future.
    Eur J Heart Fail. 2018 Oct 19. doi: 10.1002/ejhf.1320.
    >> Share

  765. FERREIRA JP, Metra M, Mordi I, Gregson J, et al
    Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study.
    Eur J Heart Fail. 2018 Oct 19. doi: 10.1002/ejhf.1323.
    >> Share

  766. LILJEROOS M, Stromberg A
    Introducing nurse-led heart failure clinics in Swedish primary care settings.
    Eur J Heart Fail. 2018 Oct 19. doi: 10.1002/ejhf.1329.
    >> Share

  767. WOLLERT KC
    Growth differentiation factor-15 reveals the dark side of heart failure.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1327.
    >> Share

  768. SEQUEIRA V, Maack C
    Rebalancing protein phosphorylation in heart failure to prevent arrhythmias.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1315.
    >> Share

  769. CIKES M, Sanchez-Martinez S, Claggett B, Duchateau N, et al
    Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1333.
    >> Share

  770. CAMPBELL RT, Petrie MC, McMurray JJV
    Redefining heart failure phenotypes based on ejection fraction.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1325.
    >> Share

  771. PABEL S, Wagner S, Bollenberg H, Bengel P, et al
    Empagliflozin directly improves diastolic function in human heart failure.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1328.
    >> Share

  772. MCDONAGH T, Damy T, Doehner W, Lam CSP, et al
    Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice.
    Eur J Heart Fail. 2018 Oct 12. doi: 10.1002/ejhf.1305.
    >> Share

  773. COSTANZO MR, Ponikowski P, Coats A, Javaheri S, et al
    Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure.
    Eur J Heart Fail. 2018 Oct 10. doi: 10.1002/ejhf.1312.
    >> Share

  774. PATEL HC, Kaye DM
    Exercise training in heart failure: a long way to go yet.
    Eur J Heart Fail. 2018 Oct 9. doi: 10.1002/ejhf.1332.
    >> Share

  775. MCCARTHY CP, Vaduganathan M, Pandey A
    Developing evidence-based and accountable health policy in heart failure.
    Eur J Heart Fail. 2018 Oct 8. doi: 10.1002/ejhf.1331.
    >> Share

  776. CAMPBELL RT, Petrie MC, McMurray JJV
    Talking to patients with heart failure about end of life.
    Eur J Heart Fail. 2018 Oct 8. doi: 10.1002/ejhf.1321.
    >> Share

  777. STRENG KW, Lang CC, Voors AA
    What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? Reply.
    Eur J Heart Fail. 2018 Oct 8. doi: 10.1002/ejhf.1324.
    >> Share

  778. PAPP Z, Radovits T, Paulus WJ, Hamdani N, et al
    Molecular and pathophysiological links between heart failure with preserved ejection fraction and type 2 diabetes mellitus.
    Eur J Heart Fail. 2018 Oct 2. doi: 10.1002/ejhf.1318.
    >> Share

  779. CORRA U, Agostoni PG, Anker SD, Coats AJS, et al
    Corrigendum to 'Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology' [Eur
    Eur J Heart Fail. 2018;20:1501.
    >> Share

  780. CAPTUR G, Bilinska Z, Arbustini E
    Lamin missense mutations-the spectrum of phenotype variability is increasing.
    Eur J Heart Fail. 2018;20:1413-1416.
    >> Share

  781. TER MAATEN JM, Damman K
    Chloride, what else?
    Eur J Heart Fail. 2018;20:1444-1446.
    >> Share

  782. BORIANI G, Diemberger I
    Cardiac resynchronization therapy in the real world: need to upgrade outcome research.
    Eur J Heart Fail. 2018;20:1469-1471.
    >> Share

  783. SINAGRA G, Merlo M, Cannata A
    Gender medicine in dilated cardiomyopathy: pride and prejudice.
    Eur J Heart Fail. 2018;20:1401-1403.
    >> Share

  784. SKELIN M, Lucijanic M, Javor E
    Risk stratification according to insulin type.
    Eur J Heart Fail. 2018;20:1497.
    >> Share

  785. LECLERCQ C, Galand V, Behar N, Martins R, et al
    I had a dream....
    Eur J Heart Fail. 2018;20:1482-1484.
    >> Share

  786. COSMI F, Staszewsky L, McMurray JJV, Latini R, et al
    Risk stratification according to insulin type: reply.
    Eur J Heart Fail. 2018;20:1498.
    >> Share

  787. AL-SAAIDI RA, Rasmussen TB, Birkler RID, Palmfeldt J, et al
    The clinical outcome of LMNA missense mutations can be associated with the amount of mutated protein in the nuclear envelope.
    Eur J Heart Fail. 2018;20:1404-1412.
    >> Share

  788. LINDE CM, Normand C, Bogale N, Auricchio A, et al
    Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II.
    Eur J Heart Fail. 2018;20:1457-1468.
    >> Share

    September 2018
  789. TAYLOR RS, Walker S, Smart NA, Piepoli MF, et al
    Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials.
    Eur J Heart Fail. 2018 Sep 26. doi: 10.1002/ejhf.1311.
    >> Share

  790. MULLENS W, Verbrugge FH, Nijst P, Martens P, et al
    Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
    Eur J Heart Fail. 2018 Sep 21. doi: 10.1002/ejhf.1307.
    >> Share

  791. KOEHLER F, Koehler K, Deckwart O, Prescher S, et al
    Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and descrip
    Eur J Heart Fail. 2018 Sep 19. doi: 10.1002/ejhf.1300.
    >> Share

  792. GREENBERG B, Fang J, Mehra M, Stevenson LW, et al
    Advanced heart failure: Trans-Atlantic perspectives on the Heart Failure Association of the European Society of Cardiology position statement.
    Eur J Heart Fail. 2018 Sep 18. doi: 10.1002/ejhf.1313.
    >> Share

  793. VENTURA HO, Carbone S, Lavie CJ
    Muscling up to improve heart failure prognosis.
    Eur J Heart Fail. 2018 Sep 18. doi: 10.1002/ejhf.1314.
    >> Share

  794. PACKER M
    The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction.
    Eur J Heart Fail. 2018 Sep 17. doi: 10.1002/ejhf.1294.
    >> Share

  795. VOORS AA, Shah SJ, Bax JJ, Butler J, et al
    Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.
    Eur J Heart Fail. 2018 Sep 17. doi: 10.1002/ejhf.1295.
    >> Share

  796. BOUABDALLAOUI N, Claggett B, Zile MR, McMurray JJV, et al
    Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.
    Eur J Heart Fail. 2018 Sep 11. doi: 10.1002/ejhf.1301.
    >> Share

  797. FISCHER TH, Eiringhaus J, Dybkova N, Saadatmand A, et al
    Activation of protein phosphatase 1 by a selective phosphatase disrupting peptide reduces sarcoplasmic reticulum Ca(2+) leak in human heart failure.
    Eur J Heart Fail. 2018 Sep 7. doi: 10.1002/ejhf.1297.
    >> Share

  798. PALECZNY B, Olesinska-Mader M, Siennicka A, Niewinski P, et al
    Assessment of baroreflex sensitivity has no prognostic value in contemporary, optimally managed patients with mild-to-moderate heart failure with reduced ejection fraction: a retrospective analysis of 5-year survival.
    Eur J Heart Fail. 2018 Sep 6. doi: 10.1002/ejhf.1306.
    >> Share

  799. METRA M
    September 2018 at a glance: co-morbidities, heart failure with preserved ejection fraction and mineralocorticoid receptor antagonists.
    Eur J Heart Fail. 2018;20:1245-1246.
    >> Share

  800. BUTLER J, Vijayakumar S, Pitt B
    Revisiting hyperkalaemia guidelines: rebuttal.
    Eur J Heart Fail. 2018;20:1255.
    >> Share

  801. BAYES-GENIS A, Lupon J, Nunez J
    No urgent need for revisiting kalaemia guidelines: rebuttal.
    Eur J Heart Fail. 2018;20:1256.
    >> Share

  802. MAGGIONI AP
    Smartphones, barbershops, and pharmacists to improve adherence to drug treatment in chronic cardiovascular conditions: the end justifies all the means.
    Eur J Heart Fail. 2018;20:1360-1362.
    >> Share

  803. BAYES-GENIS A, Lupon J, Nunez J
    No need for urgent revisiting of kalaemia levels in guidelines despite use of mineralocorticoid receptor antagonists: bring in more evidence.
    Eur J Heart Fail. 2018;20:1252-1254.
    >> Share

    August 2018
  804. LUO N, O'Connor CM, Cooper LB, Sun JL, et al
    Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION.
    Eur J Heart Fail. 2018 Aug 31. doi: 10.1002/ejhf.1299.
    >> Share

  805. EMAMI A, Saitoh M, Valentova M, Sandek A, et al
    Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
    Eur J Heart Fail. 2018 Aug 30. doi: 10.1002/ejhf.1304.
    >> Share

  806. CAO TH
    What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure?
    Eur J Heart Fail. 2018 Aug 23. doi: 10.1002/ejhf.1303.
    >> Share

  807. GODINO C, Scotti A, Munafo A, Taramasso M, et al
    Observed versus predicted mortality after MitraClip treatment in patients with symptomatic heart failure and significant functional mitral regurgitation.
    Eur J Heart Fail. 2018 Aug 23. doi: 10.1002/ejhf.1291.
    >> Share

  808. TROMP J, Teng TH, Tay WT, Hung CL, et al
    Heart failure with preserved ejection fraction in Asia.
    Eur J Heart Fail. 2018 Aug 16. doi: 10.1002/ejhf.1227.
    >> Share

  809. GRAZIANI F, Varone F, Crea F, Richeldi L, et al
    Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis.
    Eur J Heart Fail. 2018 Aug 7. doi: 10.1002/ejhf.1286.
    >> Share

  810. GAGLIARDI C, Perfetto F, Lorenzini M, Ferlini A, et al
    Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
    Eur J Heart Fail. 2018 Aug 2. doi: 10.1002/ejhf.1285.
    >> Share

  811. VAN WOERDEN G, Gorter TM, Daan Westenbrink B, Willems TP, et al
    Epicardial fat in heart failure patients with mid-range and preserved ejection fraction.
    Eur J Heart Fail. 2018 Aug 1. doi: 10.1002/ejhf.1283.
    >> Share

  812. CLERICO A, Passino C, Emdin M
    The paradox of low B-type natriuretic peptide levels in obesity revisited: does sex matter?
    Eur J Heart Fail. 2018;20:1215-1216.
    >> Share

  813. PIZARD A
    In need of signalling pathway data.
    Eur J Heart Fail. 2018;20:1202-1204.
    >> Share

  814. COOPER LB, Hernandez AF
    Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy.
    Eur J Heart Fail. 2018;20:1227-1229.
    >> Share

  815. MADIAS JE
    Tachycardia and hypotension in patients with takotsubo syndrome: any insights about their management?
    Eur J Heart Fail. 2018;20:1243.
    >> Share

  816. METRA M
    August 2018 at a glance: patients' outcomes, obesity and medical therapy.
    Eur J Heart Fail. 2018;20:1167-1168.
    >> Share

  817. SUTHAHAR N, Meijers WC, Ho JE, Gansevoort RT, et al
    Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population.
    Eur J Heart Fail. 2018;20:1205-1214.
    >> Share

  818. GUPTA A, Fonarow GC
    The Hospital Readmissions Reduction Program-learning from failure of a healthcare policy.
    Eur J Heart Fail. 2018;20:1169-1174.
    >> Share

  819. TREVISAN M, de Deco P, Xu H, Evans M, et al
    Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.
    Eur J Heart Fail. 2018;20:1217-1226.
    >> Share

    July 2018
  820. MAGINI A, Farina S, Riggio D, Sandri MT, et al
    ST2 and B-type natriuretic peptide kinetics during exercise in severe heart failure.
    Eur J Heart Fail. 2018 Jul 27. doi: 10.1002/ejhf.1246.
    >> Share

  821. COTTER G, Davison BA
    Unmodifiable events, heart failure research, and 'risk-based monitoring' in large studies-the unholy triumvirate.
    Eur J Heart Fail. 2018 Jul 27. doi: 10.1002/ejhf.1282.
    >> Share

  822. SCHMITTO JD, Pya Y, Zimpfer D, Krabatsch T, et al
    Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study.
    Eur J Heart Fail. 2018 Jul 27. doi: 10.1002/ejhf.1284.
    >> Share

  823. DOEHNER W, Celutkiene J, Haeusler KG
    Central command in heart failure: was there effect of hemispheric lateralization in insular cortex activation? Reply.
    Eur J Heart Fail. 2018 Jul 13. doi: 10.1002/ejhf.1281.
    >> Share

  824. CARBONE S, Elagizi A, Lavie CJ
    Obesity and mortality risk in heart failure: when adipose tissue distribution matters.
    Eur J Heart Fail. 2018 Jul 12. doi: 10.1002/ejhf.1279.
    >> Share

  825. MAHMOOD SS, Patel RB, Butler J, Vaduganathan M, et al
    Epirubicin and long-term heart failure risk in breast cancer survivors.
    Eur J Heart Fail. 2018 Jul 4. doi: 10.1002/ejhf.1215.
    >> Share

  826. STRENG KW, Voors AA, Hillege HL, Anker SD, et al
    Waist-to-hip ratio and mortality in heart failure.
    Eur J Heart Fail. 2018 Jul 2. doi: 10.1002/ejhf.1244.